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SUMMARY 
 
Parkinson’s disease (PD) is a chronic neurodegenerative disorder which is 
characterized by motor disability as well as non-motor impairment including 
cognitive, emotional, sensorial and autonomic aspects. Self-reported Health Related 
Quality of Life (HRQoL) of PD patients is increasingly being recognized as an 
important outcome measure in assessing patients’ well-being. Being a chronic disease 
with much impact on a patient’s functional status and well being, PD exerts a 
substantial economic burden to society as a whole. Coupled with the increasing 
prevalence of PD, a better understanding of the pharmacoeconomics issues related to 
PD is important. However, evidence for disease impact on HRQoL and 
pharmacoeconomics of treatments in Asian PD patients is lacking. The aims of this 
thesis were therefore to evaluate the impact of disease on HRQoL and 
pharmacoeconomic outcomes among Asian patients with PD.  
 
In the first part of this thesis, we measured HRQoL and identified factors that 
were associated with HRQoL among PD patients in a cross-sectional study. We then 
went on to evaluate if the 8-item Parkinson’s Disease Questionnaire (PDQ-8) is 
capable of detecting important changes in HRQoL for it to be incorporated in 
longitudinal studies. In addition, we estimated the minimally important difference in 
change score of PDQ-8 to facilitate interpretation of HRQoL scores by end users such 
as clinicians and patients. In summary, we found that both socio-demographics such 
as survey language and clinical variables such as duration and severity of PD were 
associated with HRQoL among Asian patients with PD. Additionally, we found the 
PDQ-8 to be a reliable and responsive measure for assessing changes in HRQoL over 
time among patients with PD. The MID of the PDQ-8 was found to range from 5.8 to 
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7.4 points, thus setting a reference benchmark to facilitate the use of the instrument in 
clinical practice.  
 
In the second part of the thesis, we evaluated the annual and lifetime cost of 
PD. In addition, we also performed a cost-effectiveness analysis of selegiline (an anti-
parkinsonian alternative) over other anti-parkinsonian drugs. Economically speaking, 
our study showed that PD exerted a considerable economic burden on society with a 
total cost of between SGD26-46 (USD purchasing power parity (PPP) 23-41) million 
per annum in Singapore. Additionally, total life-time economic burden in a cohort of 
Singaporean PD patients amounted to be SGD61206 (USD PPP 54648) per patient. 
These monetary values would provide a base for comparison of cost-benefit of newer 
but more expensive management strategy for PD. In the cost-effectiveness analysis, 
selegiline was found to be cost-effective in reducing disease progression.   
 
In conclusion, we have contributed new knowledge with regards to PD 
management in Singapore and the findings from this thesis will potentially facilitate 
rational medical decision making by incorporating both economic and humanistic (i.e. 
HRQoL) outcomes in addition to clinical outcomes. The findings in 
pharmacoeconomic evaluations are expected to contribute towards the development 
of pharmacoeconomic guidelines in Singapore as well as benefit other countries in the 
region that aim to incorporate pharmacoeconomics data in evidence-based medical 
decision making.  
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Research in Health Related Quality of Life (HRQoL) and Pharmacoeconomics 
have evolved and advanced rapidly in the past decades. This thesis will begin with a 
brief introduction of HRQoL and pharmacoeconomics to highlight their potential and 
importance in health service and clinical delivery. An overview of Parkinson’s disease 
(PD) will subsequently be provided as it sets the context for the studies in this thesis. 
The research objectives will be summarized at the end of this chapter and reiterated in 
the individual chapters.  
 
Overview of Health-related Quality of Life (HRQoL)  
Over past two decades, traditional measures of public health based on 
morbidity or mortality are no longer adequate in their ability to inform healthcare 
decision making in the context of an epidemiology shift from acute illness to chronic 
conditions. Additionally, there is greater emphasis on patients’ autonomy in the 
management of their own conditions. Hence, HRQoL which is a patients’ self-
reported measure of perceived impact of diseases and treatments, is increasingly being 
measured. Although there is no formal agreement on the definition of HRQoL, it is 
generally accepted that HRQoL includes physical, mental and social domains of 
functioning and well-being.1 
 
For the purpose of categorization, HRQoL instruments could be divided into 
generic and disease specific instruments. Generic instruments are applicable to a wide 
range of health-related conditions and therefore allow comparisons amongst different 
patient groups. Some notable examples of generic instruments include the Short Form 
36 health survey (SF-36)2 and EuroQol (EQ-5D).3 On the other hand, disease specific 
measures cover areas that may be only relevant to the disease or disorder in question 
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and highlight areas considered to be of particular importance to the patients that might 
otherwise not be assessed when other clinical measures, such as generic instruments, 
are used. This allows the instrument to be more responsive or sensitive changes in 
HRQoL to a particular patient group. To date, the most commonly used HRQoL 
questionnaire in PD is the 39-item Parkinson’s Disease Questionnaire (PDQ-39).4 
Meanwhile, the shorter version 8-item Parkinson’s Disease Questionnaire (PDQ-8) of 
PDQ-39 has been increasingly applied in busy clinics due to its lower respondent 
burden compared to its parent version.5   
 
Alternatively, HRQoL instruments can also be classified as profile-based and 
preference-based instruments. Profile-based instruments typically comprise two or 
more domains of HRQoL with each domain having a domain score, thus generating a 
profile of health status. Sometimes, the related domains can be grouped together to 
yield summary scores. SF-36 is a popular profile-based instrument generating 8-
domain scores.2 Furthermore, the 8 domain scores can be used to calculate physical 
and mental summary scores. Unlike profile-based measures, preference-based 
measures generate a single utility score which reflects the preference placed on 
measured health outcomes by patients or the general public. The utility scores are 
widely applied in combination with survival data to calculate Quality-Adjusted Life 
Years (QALYs), which is a useful measure of outcomes for conducting 
pharmacoeconomic evaluation. One of the most popular preference-based instruments 
is the EQ-5D which is made up of a self-classifier and a visual analogue scale (VAS).3 
The self-classifier comprises five dimensions including mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression, with each dimension described as 
having no problems, moderate problems, or severe problems. A total of 243 possible 
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health states can be determined and valued with a utility index score. The VAS is a 
vertical and graduated 20 cm “feeling thermometer” anchored by 0 at the bottom 
(representing worst imaginable health status) and 100 at the top (representing best 
imaginable health status).     
 
Regardless of whether the HRQoL instruments are generic or disease specific, 
they should satisfy basic psychometric properties including reliability, validity and 
responsiveness before they can be clinically useful. Generally speaking, reliability 
refers to the ability of the instrument to generate consistent measurements, validity 
refers to the ability of the instrument to measure what it is supposed to measure and 
responsiveness refers to the ability of an instrument to detect changes over time.
6
 In 
order to be useful for research and clinical practice, a HRQoL instrument should 
possess the acceptable psychometric properties mentioned above.  
 
Overview of Pharmacoeconomics 
In the face of ever increasing demand for health care and scare health 
resources available, pharmacoeconomics has received increasing attention in 
healthcare research and medical decision making in the past decades. 
Pharmacoeconomics is a discipline concerned with evaluating the costs and benefits 
of pharmaceuticals and pharmaceutical services from the perspectives of the 
individuals, the health care system and the society. It is a tool that is increasingly 
employed by decision makers in setting priorities for resource allocation.7 
Pharmocoeconomics research identifies, measures and compares the costs (including 
healthcare resources consumed and productivity losses) and consequences (including 
clinical, economic and humanistic outcomes) of pharmaceutical products and 
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services.
8
 Within this framework, the popular economic evaluation methods used 
include cost of illness (COI) analysis, cost-minimization analysis (CMA), cost-
effectiveness analysis (CEA) and cost-utility analysis (CUA).9 A COI study identifies 
and estimates the overall cost of a particular disease in a defined population. In 
general, COI may be estimated using the prevalence and incidence based approaches, 
which are complementary. Prevalence approach involves estimating for any disease 
the direct costs and productivity loss attributable to all cases occurring in a given year. 
The incidence approach involves estimating the lifetime costs of the new cases of a 
condition which have their onset in a given period. On the one hand, the prevalence 
based approach is particularly useful for planning of the cost containment as well as 
health care training and facility policies. On the other hand, the incidence based 
approach allows one to evaluate the long-term economic implications of alternative 
interventions albeit needing much more time and resources to conduct the study.10 
Unlike the other methods, COI analysis does not measure efficacy. Among the 
methods that measure both costs and consequences, CMA is a tool used to compare 
two or more treatment alternatives that are equal in effectiveness. When treatment 
alternatives are not therapeutically equivalent, CEA will be a more appropriate 
evaluation method. However, since CEA values outcomes in natural units, for 
example life-year saved, death prevented, etc. it cannot be used to make comparison 
of CEA across a broad set of interventions as the outcomes are dissimilar (e.g. per 
mmHg reduction in blood pressure vs. per kg weight loss) or when there is more than 
one outcome of interest, for example, both life extension and death prevented. Under 
these circumstances, CUA helps to address the limitation of CEA by providing a 
means through which the various disparate outcomes can be combined into single 
summary outcome index such as QALYs which is calculated by multiplying the 
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length of time by the utility value of the health outcomes during the time period. The 
advantage of the QALYs as a measure of health output is that it can simultaneously 
capture gains from reduced morbidity (quality gains) and reduced mortality (quantity 
gains).8, 11 Given its fundamental roots in health economics and evidence-based 
outcome research, pharmacoeconomics has therefore been recognized as a useful 
scientific tool and has been adopted by several health regulatory agencies such as 
Australia, Canada and the UK to inform drug reimbursement decisions.12-14  As a 
decision science, it is also gaining increasing acceptance among regulators and 
decision makers countries in the Asia Pacific regions.15 
 
Overview of PD 
Epidemiology 
PD is a chronic, progressive neurodegenerative disorder that is characterized 
clinically by resting tremor, rigidity, bradykinesia (slowness in movement) and 
postural instability, and non-motor symptoms including cognitive, emotional, 
sensorial and autonomic dysfunction.
16
 It was first formally described in “An Essay 
on the Shaking Palsy” published in 1817 by James Parkinson.17 The prevalence rates 
of PD vary between 18 and 418 per 100,000 worldwide.18 An estimated 400,000 to 
600,000 people in US are living with PD.19 This is projected to grow to 1.3 million by 
the year 2040.20 Age is the single most consistent risk factor, and with the increasing 
aging of the general population, PD is becoming a relatively common disease among 
the elderly of all ethnic groups and socio-economic classes in many countries 
throughout the world.18 Beside age, the other contributing risk factors are 
environment agents and generic factors as stated in Section 1.3.2. In Singapore, a 
three-phase community-based survey estimated the prevalence of PD to be 0.3%, with 
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the age and sex-adjusted incidence rate of 32 per 100,000.
21, 22
 The age-adjusted 
prevalence rates among Chinese (0.33%, 95% CI: 0.22 to 0.48), Malays (0.29%, 95% 
CI: 0.13 to 0.67), and Indians (0.28%, 95% CI: 0.12 to 0.67) were the same (p = 
1.0).23 Meanwhile, as the population is aging rapidly with the percentage of elderly is 
projected to increase to 27% by the year 203024, the prevalence of PD in Singapore 
would be expected to rise quickly in the coming years.  
 
Etiology and pathophysiology of PD  
To date, the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
is the only environmental agent identified so far that is capable of causing 
parkinsonism, even though other environmental factors such as use of pesticides and 
herbicides have been linked with an increased risk of disease.25, 26 There is increasing 
evidence for a genetic component in the cause of PD. Several population-based 
studies have found a 2-3 fold increased risk of developing PD among first degree 
relatives of a patient.27 In addition, the prevalence of PD in Asian countries was 




PD is a disorder of involving the basal ganglia which functions to maintain 
posture and muscle tone and regulate voluntary smooth motor activity.29, 30 Dopamine 
functioning as the inhibitory neurotransmitter is progressively lost in the nigrostraital 
tracts located at basal ganglia and acetylcholine acting as the excitatory 
neurotransmitter is relatively increased. The deficiency of dopamine is primarily 
responsible for the manifestations of the disease and drug therapy is used to correct 
this imbalance.31, 32   
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Overview of anti-parkinsonian treatments in PD  
Almost 40 years after its introduction, levodopa-carbidopa remains the most 
efficacious drug for the treatment of PD.33 However, its effectiveness with long-term 
administration typically requires dose escalation33 and up to 80% of patients 
eventually develop motor complications.34 Motor complications (i.e. on/off 
fluctuations and dyskinesias) are a frequent source of disability in patients with PD, 
substantially reducing their HRQoL.35 Medications from a number of drug classes i.e. 
dopamine agonist are often given adjunctively to mitigate motor fluctuations during 
levodopa-carbidopa therapy or are increasingly considered as initial therapy for 
delaying levodopa-carbidopa related motor fluctuations and dyskinesias. Currently, 
none of these medications completely prevent or alleviate motor complications and all 
are associated with side effects.35 Research is under way to improve the long-term 
efficacy, safety and tolerability of medications for patients with PD and to identify a 
therapy that slows or prevents progression.36 A list of commonly used drugs for the 
management of PD is presented in Table 1.1. 
 
Table 1.1 Commonly used drugs for the management of PD37 
 




Levodopa-carbidopa  Monotherapy or 


















Monoamine oxidase Monotherapy or No evidence Possibly 
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Monotherapy or in 
combination with other 
therapies 
No evidence No evidence 
 
Of the many treatment options investigated, the most promising has been the 
use of monoamine oxidase type B (MAO-B) as a possible disease modifying drug.  
The ADAGIO study concluded that early treatment with rasagiline at a dose of 1mg 
per day provided benefits that were consistent with a possible disease-modifying 
effect.
38
 Rasagiline is however not widely available globally.  Its use has so far been 
primarily restricted to North America and Europe with many other regions of the 
world depending on selegiline for MAO-B inhibition.  The results of a number of 
clinical trials suggest that the use of selegiline in early PD may slow disease 
progression and improve long-term outcomes.
39-41
 However, up to now, there is still 
no solid conclusion on the disease modifying effect of selegiline.  
 
HRQoL and Pharmacoeconomics in PD 
PD primarily affects a patient’s motor function as well as his non-motor 
functions including cognitive, emotional, sensorial and autonomic aspects. As these 
non-motor symptoms contribute to the psychosocial consequences of this disease, 
health care professionals has recognized that it is important to assess the health status 
of a PD patient from his own perspective. As such, the patient’s self-report of his 
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health status and the perceived impact of disease and treatment on his life is 
increasingly sought after. Being defined as “a subjective assessment of the impact of 
disease and treatment including physical, mental and social domains of functioning 
and well-being”, HRQoL has therefore been one of the most important patient 
reported outcome measures in the past two decades.1 Other patient reported outcome 
measures include treatment satisfaction
42
 and medication adherence
43
, etc.  
 
Being chronic in nature, PD poses a significant economic burden on the 
individuals as well as society. Coupled with the increasing prevalence of PD, a better 
understanding of the pharmacoeconomics issue associated with PD is therefore 
important. Research is needed to identify the main cost drivers in PD so as to provide 
decision makers with information for implementing effective targeted cost control and 
resource allocation. In addition, in the face of growing availability of expensive 
therapeutic alternatives for PD amid scare health resources, pharmacoeconomic 
evaluations are needed to inform the selection of cost-effective treatments within 
budget constraints.  
 
Research Objectives 
With these as the background, this thesis was conducted to evaluate the 
HRQoL and pharmacoeconomic outcomes associated with PD in the context of 
Singapore, a multi-ethnic population in Asia. Singapore would make an interesting 
case study in two important ways:  
 
1) Singapore has a multi-ethnic population, consisting of Chinese (74% of the 
total population), Malays (14% of the total population) and Indians (9% of the total 
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population),
44
 most of whom may share similar socio-cultural background with their 
counterparts in China, Malaysia and India. Hence, with this unique position, the 
results generated from Singapore would serve as useful references for researchers in 
the other Asian countries. We are aware that healthcare systems vary from country to 
country. Yet, there is greater similarity in the healthcare system of Asian countries 
than between Asian and Western countries. For example, there are no welfare states in 
Asia and the proportion of out-of-pocket payment is higher among Asian countries 
compared to Western countries.45 Hence, our data would serve as useful references to 
other Asian countries which may lack the resources to conduct their own studies. 
 
2) Many countries in Asia are attempting to incorporate pharmacoeconomics 
information in medical decision making and Singapore is one of them.46 The findings 
of this thesis are expected to contribute towards the future development of 
pharmacoeconomic guidelines in Singapore. The top cost determinants identified in 
this thesis would serve as a benchmark for Asian countries that are looking into cost 
containment. Furthermore, many Asian health care systems rely on published 
economic evaluation rather than perform their own country-specific studies due to 
shortage of monetary and manpower resources. Hence, our findings among Asians 
would be of greater relevance compared to findings from studies conducted in a 
Western population. 
 
While HRQoL and pharmacoeconomic evaluations in PD are common in 
western countries, there is a paucity of published literature in Asian patients. We 
attempted to provide insights into the HRQoL and pharmacoeconomic issues 
encountered by patients with PD in Singapore over the next seven chapters. 
Chapter 1. Introduction                                                                            Zhao, Yingjiao 
 
  12  
 
First, we measured HRQoL among PD patients in a cross-sectional study and 
identified factors that were associated with HRQoL in this sample (Chapter 2). We 
then went on to evaluate if the 8-item Parkinson’s Disease Questionnaire (PDQ-8) is 
capable of detecting important changes in HRQoL for it to be incorporated in 
longitudinal studies (Chapter 3). In addition, we estimated the minimally important 
difference in change score of PDQ-8 to facilitate interpretation of HRQoL scores by 
end users such as clinicians and patients (Chapter 3). 
 
In the second part of the thesis, we proposed a new approach to model the 
progression of PD based on the modified Hoehn and Yahr (H&Y) staging (Chapter 4). 
This would form the basis of the state transition economic model used to evaluate the 
annual and lifetime cost of PD (Chapters 5 and 6, respectively). In addition, an 
alternative approach has been adopted to estimate effect of selegiline (an anti-
parkinsonian alternative) on the progression of early-stage PD (Chapter 7). To 
illustrate how HRQoL and economic data may be combined, we performed a cost 
utility analysis of treatment incorporating selegiline over treatment not incorporating 
selegiline in early PD in Chapter 8. 
 
 Overall, the studies as presented in this thesis attempted to fill in the 
knowledge gaps (i.e. paucity of data) on HRQoL and pharmacoeconomic evidence in 
Asian countries. By identifying factors affecting HRQoL and determinants of cost in 
PD, we could devise effective targeted interventions to improve HRQoL and reduce 
health care cost. We have also demonstrated that the use of treatment incorporating 
selegiline is cost-effective and should be considered for patients with PD. By 
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advocating the use of cost-effective therapies, we are able to stretch the health care 
dollars further.  











Factors Affecting Health Related Quality of Life Amongst 
Asian Patients with Parkinson’s Disease 
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INTRODUTION 
Parkinson’s disease (PD) is a chronic, progressive neurological disorder with a 
substantial impact on the quality of life of patients. Health care professionals have 
recognized that enhancement of health-related quality of life (HRQoL) should be an 
important objective of medical care for PD patients. Thus, measurement of HRQoL 
and identification of factors that affect HRQoL would help to improve the 
management of PD. A number of studies have examined factors associated with poor 
HRQoL in PD patients. It has been reported that having depression,47-54 having 
cognitive impairment,47-49 higher Unified Parkinson’s Disease Rating Scale 
(UPDRS),49-53 higher Hoehn & Yahr stage (H&Y stage)49, 50, 52, 54 and longer duration 
of PD
51, 52, 55
 are associated with worse patients’ HRQoL. However, conflicting results 
about the influence of gender,47, 49, 53 age47-50, 53, 55 and education attainment51, 52 on 
HRQoL have been reported. One of the reasons for these conflicting findings may be 
the ethnic or cultural differences in health belief and attitudes towards PD because 
HRQoL is a subjective construct. Thus, it is necessary to study the effects of various 
socio-demographic factors on the HRQoL in patients with PD from different cultural 
settings. The aim of this study was to evaluate the HRQoL of patients with PD in 
Singapore, with special emphasis to investigate the effect of socio-demographic 
factors such as gender, age, and ethnic group as well as disease-specific variables, 
such as duration of PD, H&Y stage, and the UPDRS motor score on HRQoL of 
patients with PD. Singapore is a multi-ethnic South-East Asia country comprising 
75.2% Chinese, 13.6% Malays and 8.8% Indians and 2.4% others56 where all races 
have good and equal access to healthcare and education which is heavily subsidized. 
To the best of our knowledge, no study has been performed to determine the factors 
that influence HRQoL amongst Chinese patients with PD or in South-East Asia. The 
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elicitation of factors affecting HRQoL among Asian PD patients would contribute to 
better management of this condition whose incidence will increase in the years to 
come because of the rapidly ageing population in this region. 
 
METHODS 
Subjects and study design 
A consecutive sample of patients seen at a tertiary neuroscience clinic between 
November 2004 and September 2005 was recruited for the study. All patients who 
could read English or Chinese and met the National Institute of Neurological 
Disorders and Stroke (NINDS) criteria57 for the diagnosis of Parkinson’s disease were 
included; patients with concurrent dementia or with Chinese Mini Mental State 
(cMMSE)58 of 20 or less were excluded from the study. A previous study showed that 
20 is the optimal cut-off point for dementia in Singapore when using the MMSE.59  
 
All participants were asked to self-administer the 8-item Parkinson’s Disease 
Questionnaire (PDQ-8) in a clinic setting. Patients chose to answer the English or 
Chinese version of the PDQ-8 based on their own ability and preference. Parkinsonian 
disability and severity were assessed using the H&Y stage scale60 and the motor score 
of the UPDRS by neurologists on the day of the survey.61 The H&Y stage scale 
assesses patients with PD using a 5-stage score in terms of their unilateral (H&Y stage 
1) versus bilateral involvement (H&Y stage 2), normal balance versus postural 
instability with independence in daily activities (H&Y stage 3), and the ability to walk 
with assistance (H&Y stage 4) versus wheelchair dependency (H&Y stage 5) in 
patients who are severely disabled. The motor score of the UPDRS is a standardized 
measure of severity of PD based on the presence and severity of tremor, rigidity, 
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bradykinesia or akinesia, posture, gait and postural instability..
61
 The ratings of H&Y 
and UPDRS scores were performed by two trained movement disorder specialists. 
Information on gender, age, ethnicity, education level, and duration of PD was 
obtained from a review of medical records. This study was approved by the 




The PDQ-862 (See Appendix I) is derived from the 39-item Parkinson’s 
Disease Questionnaire (PDQ-39).63, 64 Its 8 items measure patients’ mobility, activities 
of daily living (ADL), emotional well-being, social support, cognition, 
communication, bodily discomfort and stigma in the past 4 weeks. A summary index 
(PDQ8SI) score can be calculated to measure overall HRQoL, with higher score 
indicating worse HRQoL (range: 0 to 100). Previous studies showed that the PDQ8SI 
and the PDQ-39 summary index (PDQ39SI) scores were very close to each other at 
the group level.
62, 64, 65
 The PDQ-8 has been psychometrically validated in a number 
of countries.62, 65 In Singapore, a Chinese version of PDQ-8 was developed using 
iterative translation procedures and both the Chinese version and the UK English 
version of the PDQ-8 were validated in local patients with Parkinson’s disease.64, 66 
 
Statistical analysis 
In this study, we attempted to identify factors which affect both overall 
HRQoL and the eight health problems measured by the PDQ-8. The potential factors 
we examined were age, gender, ethnicity, education, survey language, H&Y stage 
score, motor score, and duration of PD. 
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The association between factors and PDQ8SI was identified using linear 
regression analysis. First, we examined the association between PDQ8SI and each 
factor using a simple linear regression model; then the data were further analyzed 
using a multiple linear regression model in which only factors statistically significant 
in the simple linear regression models were included as independent variables. 
 
In order to determine how the factors influenced the overall HRQoL of 
patients, we examined the association between these factors and reported health 
problems measured by eight PDQ-8 dimensions using the logistic regression analysis. 
For each dimension, patients who never or occasionally suffered from the problem 
were considered as without health problems while those who sometimes, often or 
always encountered problems were treated as with health problems. We used a 2-step 
strategy in this analysis. First, simple logistic regression analysis was conducted to 
identify the significance of each factor as a predictor of reporting or not reporting 
health problems for each dimension. Second, eight multiple logistic regression models, 
one for each PDQ dimension, were used to determine the association between 
reported health problems and the factors which were identified from the simple 
logistic regression analyses according to statistical significance.  
 
In the aforementioned regression analyses, most potential factors were coded 
into categorical variables. Age was coded into two categories: ≤ 60 years and >60 
years. Ethnicity was categorized into Chinese and others due to the small number of 
patients with other ethnicities. Likewise, education was dichotomized into two 
categories: primary school or lower and at least secondary school. H&Y stage was 
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classified as ≤ 2 and ≥ 2.5. Duration of PD and motor score were treated as 
continuous variables. 
 
All data analyses were performed with SPSS 13.0 for Windows (SPSS Inc, 
Chicago, IL). Statistical significance was set at p<0.05. 
 
RESULTS 
One hundred and eighty-three of 186 eligible PD patients we approached 
agreed to participate in this study (response rate: 98.4%). The major reason for the 
patients to reject to response was due to the tight schedule of their companion i.e. 
family members. The mean age + standard deviation (SD) of the patients was 61.0 + 
9.8 years. The majority of these patients was males (68.9%), ethnic Chinese (86.3%), 
and had at least secondary school education (65.6%) (Table 2.1). 
 
The mean ±SD for PD duration, H&Y stage and motor scores was 4.6±3.8 
years, 2.3±  0.7 and 22.0±11.0, respectively. Among the patients, 104 and 79 
completed English and Chinese questionnaires, respectively. In contrast with those 
who completed English questionnaires, patients who completed Chinese 
questionnaires had higher motor score (mean: 24.0 vs. 20.4, p=0.027, two sample t-
test) and fewer years of education (secondary school or higher: 46.8% vs. 79.8%, 
p<0.001, Chi-square test). 
 
Table 2.1 Characteristics of study patients (n=183) 
 
Characteristics Mean (SD) N (%) Median Range 
Males  126 (68.9)   
Chapter 2. Factors affecting HRQoL amongst Asian patients with PD   Zhao, Yingjiao                               
 
  19                                                                                                
Age 61.0 (9.8)  61.0 30-87 
Ethnic groups     
Chinese  158 (86.3)   
Indian  13 (7.1)   
Malay  10 (5.5)   
Others  2 (1.1)   
Education     
No education  4 (2.2)   
Primary education  59 (32.2)   
Secondary education  77 (42.1)   
Diploma/A-level education  24 (13.1)   
University education  19 (10.4)   
Duration of PD 4.6 (3.8)  4.0 0-18 
0 to <5   129 (70.5)   
< 5 to <10  35 (19.1)   
< 10 to 15  17 (9.3)   
> 15  2 (1.1)   
H&Y stage 2.3 (0.7)    
1  7 (3.8)   
2  116 (63.4)   
2.5  32 (17.5)   
3  16 (8.7)   
4  7 (3.8)   
5  5 (2.7)   
Motor score 22.0 (11.0)  20.5 6-60 
Survey language     
English  104 (56.8)   
Chinese  79 (43.2)   





Mobility  (43.2)   
Activities of daily living  (38.8)   
Emotional well-being  (39.3)   
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Social support  (24.0)   
Cognitions  (26.8)   
Communication  (35.5)   
Bodily discomfort  (48.1)   
Stigma  (44.8)   
SD: standard deviation 
Note: presence of health problems was considered if a patient’s response to a PDQ-8 
question (dimension) was sometimes, often or always. 
 
The mean±SD of PDQ8SI score for the whole group was 27.5±19.9; the 
median PDQ8SI score was 25.0 (range: 0.0 to 81.3). In terms individual PDQ-8 items, 
bodily discomfort (48.1%) and social support (24.0%) were the health dimensions 
where the most and the fewest patients reported problems with a frequency of 
“sometimes” or higher during preceding month, respectively (Table 2.1). 
 
In simple linear regression, use of Chinese survey, higher H&Y stage, higher 
motor score and longer duration of PD were significantly associated with higher 
PDQ8SI scores. In multiple linear regression analysis, only use of Chinese survey, 
higher motor score and longer duration of PD were significantly associated with 
higher PDQ8SI scores (Table 2.2). The model accounted for 20.9% of the variance in 
PDQ8SI scores. 
 
Table 2.2 Simple and multiple linear regression analysis: effect size of factors on 
PDQ8SI scores 
 
Simple linear regression Multiple linear regression Independent variable 
(reference group) Effect size P value Effect size P value 
Gender (female) 5.16 0.104 2.71 0.371 
Age (>60 years) -2.90 0.325   
Race (Chinese) 1.33 0.757   
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H&Y stage (≥ 2.5) 11.89 <0.001 4.22 0.252 
Motor score 0.64 <0.001 0.38 0.016 
Duration of PD 1.35 <0.001 1.10 0.003 
 
In simple logistic regression, gender, use of Chinese survey, H&Y stage, 
motor score and duration of PD were influenced 2 or more dimensions of the PDQ-8 
while age, ethnicity and education were not associated with any health problems 
measured by the PDQ-8 (Table 2.3). In multiple logistic regression analysis, female 
patients and patients with higher H&Y stage were more likely to report worse 
emotional well-being; patients who completed the Chinese survey reported more 
problems with mobility, cognition and stigma; patients with higher motor scores were 
more likely to report problems with ADL; patients with longer duration were more 
likely to report problems with mobility, social support, communication and stigma. 
No variable was significantly associated with bodily discomfort (Table 2.4). 
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Table 2.3 Simple logistic regression analysis: odds ratio of reporting problems with PDQ-8 dimensions  
 
Dependent variable (outcome: with problem) Independent variable 




Cognitions Communication Bodily 
discomfort 
Stigma 
Gender (female) 2.15* 1.22 2.75** 0.78 1.60 1.51 1.78 1.16 
Age (>60 years) 0.73 0.73 1.00 0.57 0.88 0.88 1.17 0.64 
Ethnicity (Chinese) 1.25 1.55 1.03 1.00 1.34 1.23 1.45 0.96 
Education (at least 
secondary education) 
0.92 0.95 1.33 1.79 0.54 1.16 0.93 0.76 
Survey language (Chinese) 2.73** 2.19* 1.58 1.83 2.74** 1.47 1.88* 1.99* 
H&Y stage (≥ 2.5) 3.45** 3.04** 2.37** 1.08 2.61** 2.03* 2.27* 1.67 
Motor score 1.07** 1.10** 1.02 1.01 1.05** 1.04* 1.03* 1.03* 
Duration of PD 1.13** 1.10* 1.06 1.13** 1.02 1.13** 1.03 1.12** 
*p<0.05; **p<0.01 (two-tailed). 
ADL:  Activity of daily living
Chapter 2. Factors affecting HRQoL amongst Asian patients with PD                                                                                     Zhao, Yingjiao 
 
  23                                                                                                
Table 2.4 Multiple logistic regression analysis: odds ratio of reporting problems with PDQ-8 dimensions  
 
Dependent variable (outcome: with problem) Independent variable 




Cognitions Communication Bodily 
discomfort 
Stigma 
Gender (female) 1.89  2.36*      
Survey language (Chinese) 2.60** 1.84   2.60**  1.83 1.92* 
H&Y stage (≥ 2.5) 1.78 0.97 1.95*  1.85 1.30 2.00  
Motor score 1.04 1.09**   1.03 1.02 1.01 1.02 
Duration of PD 1.13** 1.07  1.13**  1.12**  1.11* 
*p< 0.05; **p<0.01 (two-tailed). 
ADL:  Activity of daily living
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DISCUSSION 
In this study, we found that Asian PD patients in Singapore experienced 
impairment in functional health and well-being. The HRQoL in these subjects was 
influenced by both socio-demographic and disease-specific variables. Our study is, to 
the best of our knowledge, the first one that utilized the PDQ-8 to identify the factors 
that influence HRQoL in PD. 
 
According to the PDQ8SI, our patients had relatively better HRQoL than 
patients with PD reported in the literature.52, 54, 55, 62, 65 The relatively better HRQoL of 
our patients should be due to the fact that most of our patients were in the early stages 
of PD. The mean duration of PD for our patients was 4.6 years which was shorter than 
those reported in previous studies (range of mean duration: 6.7 to 11.9 years). With 
regard to self-reported health problems, the major complaints of patients in our study 
were related to bodily discomfort, stigma and mobility. In contrast, previous studies 
consistently showed that mobility, bodily discomfort and ADL were the three most 
impaired domains.
52, 54, 55, 62
 It is not surprising that impairment in ADL was not a 
major problem in our study patients because only a few patients were in advance 
stages (H&Y stage 4 and 5: 6.5%). The finding that stigma was a major problem for 
our patients may be due to cultural differences between Asian and Western countries. 
Asians especially Chinese have strong sense of self-dignity and a greater need for 
“face-saving”. Studies of stigma caused by mental disorders and schizophrenia also 
found that personal stigma was greater among Asians than Western patients.67, 68 
 
In our study, patients with longer duration of PD had worse HRQoL, which is 
in accordance with the results from previous studies.51, 52, 55 Based on logistic 
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regression analyses, patients with longer duration of PD experienced more problems 
with mobility, social support, communication and stigma. These associations can be 
explained by the progressive nature of PD that over time leads to more severe 
disability and therefore causes patients more health problems. The finding about 
stigma suggests that more counseling should be provided to patients with longer 
duration of PD to improve their psychological well-being. 
 
Our results showed patients with higher motor score and higher H&Y stage 
reported poorer HRQoL. The same associations were found in many previous 
studies.49-52, 54 According to logistic regression analyses, patients with higher motor 
score experienced more problems with ADL and patients with higher H&Y stage had 
more emotional problems. One previous study found that depression was associated 
with disease severity measured by H&Y stage.69 
 
Previous studies reported conflicting results on the effect of gender, education 
and age on HRQoL of PD patients. In our study, female patients had worse HRQoL 
than male patients while education and age were not associated with HRQoL. One 
possible explanation for the conflicting observation is that the association between 
these socio-demographic factors and HRQoL depends on the cultural context and 
health care system of the study population. For example, higher education level was 
associated with better HRQoL in a previous study.
51
 The reason may be that patients 
with higher educational background understand physical and psychological needs 
better and have access to better health care.51 In contrast, access to care is not an issue 
in Singapore because of the existence of a good, subsidized and accessible healthcare 
system. It therefore appears that findings about the associations between socio-
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demographic variables and HRQoL should not be generalized across countries or 
cultures without careful investigation. 
 
We also found that patients completing the Chinese survey reported worse 
HRQoL than those completing the English survey. After adjusting for other factors, 
the mean PDQ8SI score for patients who used the Chinese survey was 7.6 points 
higher than that for patients who used the English survey. This magnitude of 
difference is meaningful as a difference of 1.6 points in the PDQ39SI has been 
determined to be important.70 
 
According to logistic regression analyses, the observed difference in overall 
HRQoL was due to the fact that patients completing the Chinese survey reported more 
problems with mobility, cognitions and stigma. The explanation for this difference 
could be due to the differential item functioning (DIF) between the two language 
versions. In HRQoL assessment, DIF occurs when the probability of choosing a 
response option for certain question(s) depends on both an individual’s health status 
and other factors such as the survey language.71 The cause of DIF could be some 
unique perception or view of the disease among patients completing the Chinese 
survey. For example, patients completing the Chinese survey may be less willing to 
reveal that they are in pain compared to patients completing the English survey. 
Hence, pain scores would always be lower among patients completing the Chinese 
survey compared to patients completing the English survey. Such DIF are well 
documented in handbook of pain and aging.72 Furthermore, patients completing the 
Chinese survey are likely to be more traditional in perspective and therefore may 
overly stigmatize PD because of their traditional Chinese belief systems and this may 
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influence their response to the questions. Future studies are needed to confirm 
whether the observed language-related difference in HRQoL is real or due to chance. 
If it is real, measures should be taken to adjust for the differences in PDQ8SI scores 
when these two versions are used in the same study. 
 
Our study has some limitations. First, it is a cross-sectional study. A snap-shot 
study of exposure and outcome at a single point in time cannot determine the causal-
effective relationship between studied variables. Thus, longitudinal studies need to be 
conducted to confirm the relationship between HRQoL and its influencing factors as 
the disease progresses. Second, we did not assess depression and its impact on 
patients’ HRQoL. Depression has been found to be strongly associated with HRQoL 
in PD in previous studies.47-55 Some of our patients might have suffered from 
depression since 39.3% of the patients reported that they at least sometimes felt 
depressed. Third, relatively mild PD patients were included in our study. Thus our 
findings might not be generalized to patients in advanced stage of PD (e.g. H&Y 
score ≥  4). Fourth, due to time and resources constraint, medication history of the 
subjects was not included in the analysis. Finally, the majority of our population was 
Chinese ethnicity; hence the generalizability to other ethnicities i.e. Malay, India 
remains determined.  
 
In conclusion, using the PDQ-8, we found that both socio-demographics and 
clinical variables influence HRQoL in Asian patients with PD and that these factors 
influence different aspects of patients’ quality of life. The effect of culture-related 
factors on HRQoL assessment should be taken into account when the instrument is 
used in a multicultural setting. 










Determination of the Longitudinal Validity and Minimally 
Important Difference of the 8-item Parkinson’s Disease 
Questionnaire (PDQ-8) 
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INTRODUCTION 
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder 
that primarily affects patients’ motor function as well as cognitive, emotional, 
sensorial and autonomic aspects. Self-report Health-Related Quality of Life (HRQoL) 
has been recognized as an important outcome indicator for evaluating the 
effectiveness of health care. Measurement of HRQoL from patients’ own perception 
in PD is highly desirable because motor dysfunction together with non-motor 
disturbance such as depression and cognitive impairment affects patients’ HRQoL.47-
49  
 
To date, the most widely validated and used HRQoL questionnaire in PD is 
the 39-item Parkinson’s Disease Questionnaire (PDQ-39).73 However, its use might 
have been restricted due to its administration burden upon respondents. As such, its 
briefer version the 8-item Parkinson’s Disease Questionnaire (PDQ-8) is more 
suitable than PDQ-39 for patients to quickly and easily complete in busy clinics64, 74 




 PDQ-8 has 
been found to be representative of its parent PDQ-39 in a few validation studies.5, 64, 65, 
74, 80, 81 Due to the increasing popularity of the PDQ-8, it is necessary to further 
investigate its psychometric properties in longitudinal studies. Also unknown to PDQ-
8 users is the minimally important difference (MID) which is considered as a useful 
standard for interpreting HRQoL scores when they change over time within patients 
or differ between patients. MID is defined as the smallest difference in score that 
informed patients or proxies perceive as important and which would lead the patient 
or clinician to consider a change in the management.82, 83 
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The aim for our study was to assess the longitudinal validity of the PDQ-8 in 
terms of responsiveness and test-retest reliability and to determine the MID for PDQ-
8 using anchor-based approach in Asians with PD in Singapore.  
 
METHODS 
Subjects and study design 
A consecutive sample of patients with PD seen at a tertiary neuroscience clinic 
in Singapore between November 2004 and March 2007 was recruited. Inclusion 
criteria were: (1) the diagnosis of PD according to the National Institute of 
Neurological Disorders and Stroke (NINDS) criteria;57 and (2) ability to read English 
or Chinese. Patients with Chinese Mini Mental State (cMMSE) scores of 20 or less 
were excluded based on a previous study which showed that 20 is the optimal cut-off 
point for dementia in Singapore when using the MMSE.58, 59 Questionnaires were 
completed during two different clinic visits, with a period of 1 to 2 years apart. At the 
first visit, all participants were asked to self-administer the PDQ-8 in a clinic setting 
and information on age, gender, ethnicity, marital status, education level, and duration 
of PD was also retrieved from patients’ medical records. Patients chose to answer the 
English or Chinese version of PDQ-8 based on their own preference. At the second 
visit, in addition to the PDQ-8, patients also answered three questions assessing their 
transition since the first visit in overall health status, PD severity, and the impact of 
PD. The questions were: “(1) Compared to 1 year ago, how would you rate your 
health in general now? (2) Compared to 1 year ago, how would you rate your 
Parkinson’s disease now? (3) Compared to 1 year ago, how would you rate the overall 
impact of Parkinson’s disease on your life now?” Questions 1 and 2 were answered 
with one of five response options: “A lot better”, “A little better”, “About the same”, 
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“A little worse” and “A lot worse”. Response options for question 3 were “The impact 
is much lesser”, “The impact is a little lesser”, “The impact is about the same”, “The 





 is derived from PDQ-39.
4
 It consists of 8 of PDQ-39 items, each 
item representing one PDQ-39 dimension (i.e. mobility, activities of daily living 
(ADL), emotional well-being, social support, cognition, communication, bodily 
discomfort, and stigma). A summary index (PDQ-8SI) can be calculated to measure 
the overall HRQoL with range from 0-100. Higher PDQ-8SI scores indicate worse 
HRQoL. Both the English and Chinese versions of the PDQ-8 used in the present 
study were validated previously.64, 80, 81 
 
Statistical analysis  
Responsiveness of PDQ-8SI scores was assessed using responsiveness indices 
including Cohen’s effect size (ES)
84
, the standardized response mean (SRM)
85
 and 
Guyatt’s responsiveness index (GRI).82, 86 The responsiveness indices were calculated 
separately for patients who reported better and worse health, either “a little” or “a lot”, 
in the follow-up survey. For all indices, a value of 0.2, 0.5 and 0.8 was considered as 
small, moderate and large responsiveness, respectively.84 Test-retest reliability was 
assessed using the intraclass correlation coefficient (ICC).
87
 Data from participants 
who reported no change on health status in the follow-up survey were used for 
calculating ICC.  
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The MID of PDQ8SI scores was defined as the mean change of the scores in 
subjects who reported “a little” change in the follow-up survey in any of the three 
domains (i.e.  health status, severity of PD,  and impact of PD).88, 89 Nevertheless, the 
calculation of MID was conducted using data from subjects who reported “a little 
worse” or “a little greater” to the 3 transition questions. We did not estimate the MID 
for subjects reporting better health status because only a few of them (n ≤10) reported 
improved health status. This is in accordance with the practice used in a previous 
study of the MID for PDQ-39 scores.70     
 
All data analyses were performed with SPSS 13.0 for Windows (SPSS Inc, 
Chicago, IL). All statistical tests are two-tailed with a significant level of 0.05. 
 
RESULTS 
A total of 96 patients with mean age + standard deviation (SD) of 58.4 + 8.8 
years participated in this study (response rates: 98%). The majority of these patients 
was males (78.1%), ethnic Chinese (88.5%), and completed the survey in English 
(60.4%). At the baseline survey, the mean (SD) for duration of PD, H&Y stage and 
UPDRS motor scores for the study sample was 5.3 (4.3), 2.1 (0.3), and 19.5 (9.5), 
respectively. Detailed demographic and clinical characteristics are summarized in 
Table 3.1.  
 
Table 3.1 Characteristics of study patients at baseline (n=96) 
 
Characteristics Mean (SD) N (%) Median Range 
Age (years) 58.4 (8.8)  58.0 37-81 
Males  75 (78.1)   
Education     
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Primary education  22 (22.9)   
Secondary education  42 (43.8)   
Tertiary education  32 (33.3)   
Marital status     
Single  7 (7.3)   
Married  77 (80.2)   
Others  12 (12.5)   
Ethnicity     
Chinese  85 (88.5)   
Indian  4 (4.2)   
Malay  6 (6.3)   
Others  1 (1.0)   
Duration of PD (years) 5.3 (4.3)  4.0 0-18 
0 to <5  62 (64.6)   
< 5 to <10  20 (20.8)   
< 10 to 15  12 (12.5)   
> 15  2 (2.1)   
H&Y stage 2.1 (0.3)  2.0 1-3 
1  3 (3.1)   
2  72 (75.0)   
2.5  15 (15.6)   
3  6 (6.3)   
4  0 (0.0)   
5  0 (0.0)   
Motor score 19.5 (9.5)  17.8 6-60 
Survey language     
English  58 (60.4)   
Chinese  38 (39.6)   
SD: standard deviation  
 
The responsiveness index values for the PDQ8SI scores ranged from 0.27 to 
0.45 for patients who reported worsened overall health status (n=36) and from 0.40 to 
0.58 for patients reporting improved overall health status (n=20) in the follow-up 
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survey (Table 3.2). The responsiveness index values ranged from 0.24 to 0.38 for 
patients whose PD was reported as worsened (n=42) and ranged from 0.40 to 0.55 for 
patients who indicated that their PD was better (n=18) in the follow-up survey. Using 
self-reported impact of PD as the criterion, the range of responsiveness index values 
were from 0.21 to 0.29 for deteriorated patients (n=39) and from 0.39 to 0.68 for 
improved patients (n=13). The mean PDQ8SI scores and mean change scores for 
patients with changed health status are displayed in Table 3.2.   
 
A total of 40 (42%), 36 (38%) and 44 (46%) patients reported no change in 
overall health status, PD severity, and PD impact at follow-up survey, respectively. 
The ICC values for the stable subjects ranged from 0.64 to 0.76. The mean change in 
PDQ-8SI scores for these stable patients ranged from 1.1 to 1.9; the range of 
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Table 3.2 Responsiveness and test-retest reliability of PDQ-8SI scores  
 
 N Mean (SD) Mean difference (SD) ES SRM GRI ICC 
  Baseline Follow-up      
Health Status         
Worse 36 33.1 (18.9) 39.1 (17.9) 6.0 (22.0) 0.32 0.27 0.45  
Better 20 34.4 (19.7) 26.6 (15.4) -7.8 (16.3)* 0.40 0.48 0.58  
About the same 40 19.6 (19.6) 21.2 (17.9) 1.6 (13.4) 0.08 0.12 0.12 0.75 
PD Severity         
Worse 42 32.4 (19.1) 37.6 (18.7) 5.1 (21.1) 0.27 0.24 0.38  
Better 18 30.7 (18.9) 23.3 (14.0) -7.4 (16.7) 0.40 0.45 0.55  
About the same 36 20.8 (21.0) 21.9 (17.9) 1.1 (13.7) 0.05 0.08 0.08 0.76 
PD Impact         
Greater 39 34.3 (18.9) 38.6 (17.7) 4.3 (21.0) 0.23 0.21 0.29  
Lesser 13 30.3 (25.8) 20.2 (17.7) -10.1 (16.1)* 0.39 0.63 0.68  
About the same 44 21.2 (18.1) 23.1(17.0) 1.9 (15.0) 0.10 0.13 0.13 0.64 
 
ES: effect size 
SRM: standardized responsiveness mean 
GRI: Guyatt’s responsiveness index 
ICC: intraclass correlation coefficient  
*P< 0.05 (two tailed) 
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The mean change (95% confidence interval [95%CI]) in PDQ-8SI scores for 
patients who reported that their overall health status was “a little worse” than one year 
ago (n=28) in the follow-up survey was 7.37 (0.09, 14.64). The mean change (95%CI) 
in PDQ-8SI scores for patients whose PD severity was “a little worse” (n=33) was 
5.78 (-0.54, 12.09). The mean change (95%CI) in PDQ-8SI scores for 23 patients who 
reported that the impact of PD on their life was “a little greater” at the follow-up 
survey was 6.79 (-0.26, 13.85). 
 
DISCUSSION  
In this longitudinal study, we found that the PDQ-8SI score was both reliable 
over time and sensitive to change in measuring HRQoL of Asian PD patients in 
Singapore. We also estimated the MID of PDQ-8SI using an anchor-based approach. 
This is, to the best of our knowledge, the first study to longitudinally investigate the 
psychometric properties and estimate the MID of the PDQ-8, when it is administered 
independently of the PDQ-39.  
 
For assessing the psychometric properties and estimating the MID of the 
PDQ-8, we used 3 self-reported global rating scales to define “stable” patients and 
patients with changed health status and performed analyses for each of the 3 criteria. 
This practice, analogous to sensitivity analysis, provided us with multiple assessments 
and estimates, thus allowing us to evaluate the stability of our results. In this study, 
we found the 3 criteria led to similar results. The ICC values were higher or close to 
0.70, suggesting that the PDQ-8 is sufficiently reliable for use in longitudinal 
evaluation of PD patients at the group level.85 The small effect sizes of the change 
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scores (range: 0.05 to 0.13, Table 2) between baseline and follow-up surveys further 
support the over-time reliability of PDQ-8SI. 
 
Using self-reported changes in overall health status, PD severity, and impact 
of PD on life, we found the PDQ-8SI was responsive to both improvement and 
deterioration in health status, although the responsiveness index values for patients 
reported worsening health status were lower (Table 2). All responsiveness index 
values ranged from 0.21 to 0.68, which corresponded to small to moderate effect sizes 
according to Cohen’s criteria,84 thus suggesting responsiveness. We did not observe 
responsiveness index values suggesting large effect size in this study probably 
because our patients were in a relatively stable stage of PD or the period of 1 to 2 
years was too short to allow dramatic changes in HRQoL for PD patients. 
 
MID is an important benchmark for interpreting HRQoL scores in both cross-
sectional comparisons of patient groups and longitudinal evaluation of treatment 
benefit. Empirical methods for estimating the MID generally fall into two categories: 
anchor-based method and distribution-based method.83 Anchor-based methods 
quantify MIDs by examining the relationship between a HRQoL measure and an 
independent measure (or anchor), while distribution-based methods rely on 
variability-based statistical measures such as effect size and standardized error of 
measurement (SEM).
83
 In our study, we elected to use the anchor-based method to 
estimate the MID of the PDQ-8SI because the anchor-based approach was considered 
better than the distribution-based approach which was criticized for having no direct 
clinical relevance.89-91 Further, we used multiple patient-based anchors to follow the 
recent advocacy of using multiple anchors in MID estimation and estimate the MID as 
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a range rather than a single point estimate.
89, 90
 The MID values of PDQ-8SI in our 
study ranged from 5.8 to 7.4 points, which should be treated as preliminary estimates 
for two reasons: first, the precision of the estimates as shown by the wide 95%CIs was 
not very good; second, the estimation of MID is a complex task because no single 
method is unanimously accepted as the gold standard. Bearing this caution in mind, 
we feel that the MID estimated in the present study may serve as a tentative 
benchmark for interpreting PDQ-8SI scores in clinical studies and that more studies 
are warranted to further investigate the MID of this instrument.   
 
We recognize several limitations in our study. First, the sample size of our 
study was relatively small, so that statistical significance was not achieved in some 
tests of change score. However, our strategies for testing responsiveness and MID are 
not based on statistical significance. In addition, the use of multiple measures and 
anchors in our assessments minimized the limitation associated with the sample size. 
Second, only Asian patients with mild to moderate severity of PD were included in 
our study, thus the findings of our study may not be generalized to patients in 
advanced stages of PD or to patients elsewhere. Third, we did not use any clinical 
assessment or clinicians’ judgment as an external criterion for defining stable or 
changed health status. However, it has been suggested that patients themselves should 
be the ultimate judge of their HRQoL and patients self-reports should be better 




In conclusion, PDQ-8 is a longitudinally reliable and responsive measure for 
assessing the HRQoL in patients with PD. The MID of the PDQ-8 estimated in the 
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study will further support the use of this instrument in both clinical research and 
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INTRODUCTION 
Parkinson’s disease (PD) is a chronic neurodegenerative disorder that afflicts 
patients for as many as 1 to 2 decades of their lives. Being a progressive disease, 
various measures have been used to evaluate and chart disease severity at different 
stages in its course. Of the many measures that have been developed, the Hoehn and 
Yahr (H&Y) scale has become the most commonly and widely used scale to estimate 
the severity of PD since its introduction in 1967.94 The scale is a simple staging 
assessment that evaluates the severity of overall parkinsonism dysfunction based on 
bilateral motor involvement and the compromise of gait and balance. The original 5-
point scale (Stage 1–5) was subsequently modified to a 7-point scale that included 
stages 1.5 and 2.5 in the 1990s. Given its historic stature, the scale has been used as a 
gold standard for the testing of newly developed scales and good correlations have 
been established with standard PD ratings scales, e.g., Unified Parkinson’s Disease 
Rating Scale (UPDRS), quality of life scales, and functional imaging studies.95 A 
recent study comparing the responsiveness of various outcome measures to assess 




The H&Y scale has been used in a number of studies to evaluate disease 
progression in PD.94, 97-105 Most of these studies evaluated disease progression by 
analyzing the time taken for patients to reach a specified H&Y stage from the time of 
disease onset or study recruitment.
94, 97-103
 While the results from these studies would 
enable a longitudinal analysis of disease progression, such an approach when 
performed prospectively requires many years for completion. As a result, many such 
studies have been conducted in a retrospective manner.94, 97-102 To the best of our 
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knowledge, there has been only one prospective study of this nature that followed 
patients over 10 years.103 
 
Another approach of utilizing the H&Y scale to evaluate disease progression 
would be to analyze the time taken for patients to transit from one H&Y stage to the 
next stage. Such analyses will provide valuable information that will not only aid 
clinical practice but also, clinical studies, health services research, and healthcare 
resource planning. To the best of our knowledge, there was only one study conducted 
by Di Rocco et al. that evaluated H&Y transition times by retrospectively studying 
deceased patients with PD treated on levodopa from 1968 to 1994.104 That study was 
specifically performed to investigate the progression of patients with PD when L-dopa 
was first introduced. As such, their findings cannot be generalized to the current 
population with PD who are exposed to more diverse treatment options. We therefore 
undertook this study to estimate H&Y transition times and to evaluate factors that 
would affect H&Y transition times using a large PD database that contained 
prospectively collected information. 
 
METHODS 
With approval from the institutional ethics committee, data were retrieved 
from the Movement Disorder Database of the PD and Movement Disorders Centre of 
the National Neuroscience Institute, Singapore. The database, which contains more 
than 1,500 patients with PD, was established in the year 2002 and contains 
prospectively collected data from the initial and subsequent follow-up visits of all 
patients with PD evaluated at the Centre. The Centre serves as a secondary and 
tertiary referral centre for both public and private sectors in Singapore and follows-up 
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a large number of patients with PD at various stages of their disease at 3 to 6 monthly 
intervals. For the purpose of this study, we selected participants with the following 
criteria: (a) diagnosis of idiopathic PD; (b) at least two or more H&Y scores 
documented; (c) interval of less than 1 year between H&Y scores; (d) had not 
undergone any PD surgery. A diagnosis of idiopathic PD was made by movement 
disorder neurologists based on the National Institute of Neurological Disorders and 
Stroke (NINDS) criteria.57 Data on gender, ethnicity, age at diagnosis, duration of 
disease, modified H&Y scores, and UPDRS motor scores were obtained from the 
database. 
 
As PD is a progressive neurodegenerative disease, the basic assumption used 
in this study is that patients would progress from one H&Y stage to the next stage 
over the course of the disease. The modified H&Y staging was used for this study.95 
To provide better anchors to define H&Y Stage 2 and 2.5 in our study, Stage 2 was 
defined as patients with bilateral disease and required at most one step to regain their 
balance during the pull-test. Stage 2.5 was defined as patients with bilateral disease 
who required more than one step but were able to recover their balance spontaneously 
during the pull-test. These rating were performed by two trained movement disorder 
specialists (LT and WLA) and an experienced PD nurse clinician (PNL). 
 
To accommodate unequal follow-up times, a Kaplan-Meier (KM) survival 
analysis was adopted to investigate the time taken to progress through the various 
H&Y stages. A separate KM analysis was performed for each stage of the disease to 
analyze disease progression from H&Y Stage 1 to 2, Stage 2 to 2.5, Stage 2.5 to 3, 
Stage 3 to 4, and Stage 4 to 5. Stage 1.5 was combined with Stage 1 as there were 
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only 21 participants rated at this stage. The progression from one H&Y stage to the 
next was treated as a transition event. The entry requirement for participants to be 
included at each H&Y stage of the KM analyses was predefined as follows. 
Participants had to be in that H&Y stage at or within one year from diagnosis, or had 
been documented to transit to that stage from a previous H&Y stage. The time to the 
transition event was measured from the time of PD diagnosis for the former group or 
from the time of transition to that H&Y stage for the latter group. H&Y scores were 
obtained in the treated or “on” phase. When fluctuating H&Y scores over a period of 
time were recorded for an individual, a consensus review by two neurologists was 
performed. During the review, H&Y trends were carefully analyzed to determine the 
point of progression from one H&Y stage to another. Under such circumstances, the 
median H&Y score over a 1-year period was generally used for analyses. Participants 
with marked fluctuations in H&Y stage, whose scores could not be resolved by the 
two neurologists, those with skipped stages, or with sustained and consistent 
improvement in their H&Y scores over 1-year period, were excluded from the study. 
 
Cox regression analysis was used to examine the association between baseline 
variables for each stage and the progression to the next H&Y stages. Age-at-diagnosis, 
duration of PD, and UPDRS motor scores were coded into four groups using the 
quartiles’ approach. Due to the small number of Malay, Indian and participants of 
other ethnicities, we categorized ethnicity into Chinese and non-Chinese. All data 
analyses were performed with SPSS 17.0 for Windows (SPSS Inc, Chicago, IL). 
SPSS treated the first category in each variable as the reference group. Statistical 
significance was set at P < 0.05. 
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RESULTS 
Of 1,004 patients with PD who met inclusion criteria for database retrieval, 
220 participants did not meet specified entry requirement for KM analyses (H&Y 
score more than 1 year from diagnosis and/or no H&Y transitions during the follow-
up period) were excluded. Eleven participants with markedly fluctuating H&Y scores, 
29 with skipped H&Y stages, and 49 with sustained improvement in H&Y scores 
were also excluded from the analyses as the time of entry to an H&Y stage and exit to 
the next stage could not be accurately determined. The majority of our patients 
progressed from one H&Y stage to the next with totally 9% of participants that were 
excluded from the study because they deviated from this pattern. 
 
A total of 695 participants were included in the KM analyses, with the 
majority of them being males (57.3%) and ethnic Chinese (85.2%). The baseline 
characteristics of participants who entered each stage of the KM analyses are 
summarized in Table 4.1.  
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Table 4.1 Baseline characteristics of participants for each H&Y stage transition (n=695) 
 Stage 1 to 2 
†N=106 
Stage 2 to 2.5 
N=359 
Stage 2.5 to 3 
N=194 
Stage 3 to 4 
N=185 























‡Age at diagnosis (years) 60.4 (10.1) 64.9 (9.8) 67.1 (10.6) 66.5 (11.1) 66.8 (10.8) 
‡Duration of PD (years) 0.3 (0.5) 0.7 (1.7) 2.9 (4.0) 3.8 (4.5) 5.8 (5.0) 
‡
UPDRS score (on) 11.1 (4.5) 19.4 (7.4) 25.1 (7.4) 30.0 (9.4) 40.0 (9.5) 
†Number of patients was analyzed in each H&Y stage transition 
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The KM analyses for progression at each H&Y stage of the disease and the 
median time taken to progress from each of the stages is presented in Figure 4.1. The 
rate of H&Y transition from Stage 1 to 2, Stage 3 to 4, and Stage 4 to 5 were similar 
(log-rank test, P 50.167) while rate of transition was slowest from Stage 2 to 2.5. For 
example, by the end of 24th, 48th, and 60th months, 60.1%, 97.2%, and 100% of 
participants had transited from H&Y Stage 1 to 2, respectively. In contrast, only 
19.7%, 41.8%, and 47.2% of participants had transited from H&Y Stage 2 to 2.5, for 
the same time periods (Table 4.2). In addition, there was an interesting pattern for 
Stage 2.5-3. It appeared that there was an initial rate of transition similar to that 
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Table 4.2 Percentages of participants who progressed from one H&Y stage to the next stage over 72 months 
By the end of N months Stage 1 to 2 Stage 2 to 2.5 Stage 2.5 to 3 Stage 3 to 4 Stage 4 to 5 
12th 32.3% 7.4% 32.8% 24.0% 18.0% 
24
th
 60.1% 19.7% 49.2% 51.7% 44.5% 
36th 83.3% 30.1% 71.7% 70.5% 65.7% 
48th 97.2% 41.8% 78.7% 84.5% 84.7% 
60
th
 100.0% 47.2% 78.7% 92.2% 84.7% 
72nd †Nil 54.8% 78.7% Nil Nil 
†
None of the study subjects was censored or remained at initiating stages by the end of 72
nd
 month
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In Cox regression analysis, participants who were older when diagnosed had 
significantly shorter transit time from Stage 2 to 2.5 compared with participants who 
were younger when diagnosed. For example, participants with age-at-diagnosis more 
than 72 years were 4.58 times more likely to transit to Stage 2.5 when compared with 
participants with age-at-diagnosis less than 59 years (P < 0.001, Table 4.3). 
Participants with longer PD duration experienced significantly shorter transit times 
from Stage 2 to 2.5 and Stage 3 to 4. It was also found that participants with higher 
baseline UPDRS motor scores had significantly shorter transit times from Stage 1 to 2, 
2 to 2.5, and 4 to 5. Gender and ethnicity did not significantly influence H&Y 
transition times (Table 4.3). 
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Table 4.3  Cox regression analysis: hazard ratio for variables associated with progression in PD 
 
HR: hazard ratio, 95% CI: 95% confidence interval, Ref: reference group, Mo: months, Yr: years 
*P <0.05, **P<0.01, ***P<0.001 
†Individual categories of age at diagnosis measured in years, duration at study entry and UPDRS vary for different H&Y stage transition
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DISCUSSION 
This study evaluated the transition time from one H&Y stage to the next stage 
using a large PD database that had prospectively collected clinical information from a 
diverse PD population. Median H&Y transition times were established for a clinic-
based medically treated PD population between each of the modified H&Y stages 
analyzed. Baseline demographic and clinical information were also analyzed to 
determine which factors predicted a faster transition between H&Y stages. To our 
best knowledge, this is the first study that analyzed the progression of PD by 
evaluating H&Y transition times using KM analyses and investigated the association 
between baseline variables and different H&Y stage transitions. 
 
The median H&Y transition times were estimated in a clinic-based PD 
population who were medically treated by movement disorder specialists who adopted 
the treatment guidelines of the American Academy of Neurology.106 The transition 
times measured represent “real-life”, naturalistic estimates of disease progression as 
opposed to estimates derived from clinical trials that are conducted on select patient 
populations managed in a controlled setting. It was found that the progression from 
H&Y Stages 1 to 2, 3 to 4, and 4 to 5 were similar both in terms of rate of transition 
and also median transit times (20-26 months or about 2 years). For participants who 
entered Stage 2 from Stage 1 or at the point of diagnosis, there was a slow progression 
to Stage 2.5, which occurred at a median transit time of 62 months or about 5 years. 
This finding confirms what is seen in clinical practice where many patients remain in 
H&Y Stage 2 for an extended period of time. When comparisons were made between 
this study and a previous study that also evaluated transition times, it was
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found that the time taken to transit from H&Y Stage 1 to 2 were similar (20 vs. 18 
months).104 However, the H&Y transition times for all other stages except for 
transition from Stage 3 to 4 were longer in our study (Stage 3-4, 24 vs. 42 months; 
Stage 4-5, 26 vs. 17 months). These differences were likely related to different study 
methods, the inclusion of Stage 2.5 in our study, the current availability of 
medications, and timing of treatment. 
 
The modified H&Y scale was adopted in this study as it is the scale currently 
being used at our centre and is more widely used than the original scale by members 
of the Movement Disorder Society.95 It is recognized that, like the original H&Y scale, 
there are few formal clinimetric examinations of its reliability and validity.
95
 In a 
recent study evaluating the longitudinal metric properties of disability rating scales for 
PD, the modified H&Y scale was used as a gold standard against UPDRS ADL part, 
the Schawb and England Scale, and the Intermediate Scale for Assessment of PD.107 
These different scales were found to be strongly correlated with the modified H&Y 
scale. These results support criterion, or at least convergent validity of the modified 
H&Y scale. To our best knowledge, there are no data on the reliability of the modified 
H&Y. As such, despite our best efforts to define Stage 2 and 2.5, we are unable to 
exclude interrater variation in the rating of these stages. 
 
It has been previously reported that patients who were older at onset or 
diagnosis experienced a more rapid progression in PD.102-105, 108-117 Our results 
showed that patients who were younger when diagnosed had a longer transition time 
from H&Y Stage 2 to 2.5, thus supporting these findings. An explanation for this
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 observation could be that in older-onset patients with PD, there are increased L-dopa 
unresponsive axial motor disabilities that give rise to balance and gait disorders earlier 
in the course of the disease.117 
 
Patients with longer disease duration were associated with shorter transit time 
from H&Y Stage 2 to 2.5 and 3 to 4. This finding differed from previous studies that 
reported negative or no association.105, 118 Our results were similar to a previous study 
which reported that patients with disease durations longer than 6.8 years experienced 
a more rapid disease progression based on their UPDRS motor scores.119 One reason 
for this observation could be that compensatory mechanisms may be able to retard 
H&Y progression for the initial few years of the disease. However, with increasing 
disease duration, these mechanisms would breakdown and lead to a faster progression 
of PD later on in the disease.120 Alternatively, later in the disease new factors could 
come into play that accelerates the disease course. For example, once a patient 
reaches H&Y stage 3 and beyond, postural instability becomes a major feature of the 
disease.  These axial symptoms are thought to be due to underlying non-dopaminergic 
changes outside the classic nigrostriatal pathway, such as norepinephrine121 or 
cholinergic denervation.122  As selegiline acts primarily on the dopaminergic system 
through mechanisms related to or independent of MAO-B inhibition123, its effects on 
disease progression in advanced PD, where dysfunction of complex non-
dopaminergic systems occurs, are unlikely to be significant.   
 
 In our study, patient with higher baseline UPDRS motor scores also 
experienced a more rapid progression in multiple H&Y stage transitions (1-2, 2-2.5 
and 4-5). It is likely that those with higher baseline UPDRS motor scores belonged to 
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the akinetic-rigid form of PD, which has been associated with a faster rate of 
progression.109, 110 
 
Previous studies have reported conflicting results on the effect of gender and 
disease progression in PD.94, 102, 105, 111, 114, 119, 124 Our study showed that gender was 
not associated with disease progression, which is in accordance with the results from 
previous studies.94, 105, 114, 119 We also did not find any differences in disease 
progression between Chinese and non-Chinese Asians in our study either. Our results 
on the association between Chinese and non-Chinese Asian groups should be treated 
carefully due to the small sample in non-Chinese Asian groups.  
 
Theoretically speaking, the ideal method of evaluating disease progression in 
PD would be to prospectively evaluate patients through the course of disease from the 
point of diagnosis. Such an approach will, however, demand much resource and time. 
In our study, an alternative method of evaluating disease progression in PD by using 
H&Y transition times is presented with many findings congruent with other studies or 
clinical observations. Naturally, any instrument used to measure disease progression 
in PD will have its limitations. Even though the H&Y staging is the most widely used, 
it is recognized that disease progression using this staging system is not linear. 
However, it is remarkable that the median time of about 2 years was found in all 
H&Y stage transitions except for the transition between Stage 2 and 2.5, which took 
about 5 years. It is also recognized that all patients may not go through the spectrum 
of H&Y stages sequentially and that death may intervene at any stage. We found that 
the large majority of our patients actually did progress from one H&Y stage to the 
next. In fact, only 9% of participants were excluded from the study because they 
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deviated from this pattern. In this group of patients, their non-conformity was often 
due to complex motor fluctuations with different degrees of “on” stage and/or the 
presence or resolution of co-morbid conditions that affected H&Y staging. 
Nevertheless, the exclusion of these patients may have affected the results, and we 
recognize this as a possible limitation of our study. 
 
In conclusion, an alternative method of assessing disease progression by 
measuring H&Y transition times by KM analysis is presented. Using this method, 
estimates of the median duration at each H&Y stage have been provided. In addition, 
this surrogate measure of disease progression has supported previous studies using 
other measures of disease progression that older age at diagnosis and longer duration 
of disease are associated with faster disease progression. These findings provided 
some validity to the use of H&Y transition times as a measure of disease progression 
in PD. We also reported that higher baseline UPDRS motor scores are associated with 
more rapid H&Y transitions. This method of evaluating disease progression in PD 
warrants further evaluation and may be applied in clinical studies evaluating 
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INTRODUCTION  
PD is a chronic, progressive neurodegenerative disorder predominantly 
affecting the older population. With a rapidly aging population internationally, the 
number of PD patients worldwide is expected to double in the next 25 years,125 
potentially imposing a significant burden on the health care budget of any jurisdiction. 
Indeed, the total economic cost of PD to the USA is projected to exceed US$50 
billion by 2040.126 In Singapore, the prevalence of PD was estimated at 0.30%,23 but 
the economic burden of PD is unknown. This is likely to have an impact on decision 
making about health resource allocation in the management of PD.  
 
While cost of illness (COI) studies are common in western countries,
126-135
 
there is a paucity of published literature in Asia. So far, there are only two published 
PD COI studies in Asia136, 137 with only one adopting the societal perspective,136 the 
preferred perspective in economic analyses with its considering of alternative resource 
uses outside the health care sector.138 Without the inclusion of productivity loss, 
evaluating the economic burden of chronic diseases such as PD would not be truly 
meaningful.  
 
Furthermore, besides describing the economic burden of PD, it would be 
useful to identify factors associated with or predictive of cost. Among three studies 
that evaluated factors associated with direct PD cost,
127-129
 higher Hoehn and Yahr 
(H&Y) scores,127-129 higher Activities of Daily Living (ADL) scores127, 128 and worse 
Health Related Quality of Life (HRQoL) scores128, 129 were associated with higher 
cost in the studies that included these variables. However, these studies were 
performed among non-Asians and the findings may not be readily generalizable to 
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Asians. Hence, a better understanding of the clinical, sociodemographic and HRQoL 
factors associated with the total, direct and indirect cost of PD among Asians would 
contribute to the cost-effective management of PD in Asia.  
 
Therefore, our study aimed to estimate the annual economic burden of PD 
including direct and indirect cost over a period of 12 months among PD patients in 
Singapore, a multi-ethnic South-East Asian country comprising 74.2% Chinese, 
13.4% Malays and 9.2% Indians.139  The secondary objective was to identify clinical, 
sociodemographic and HRQoL risk factors associated with economic burden of PD.  
 
METHODOLOGY 
Subjects and study design 
In this Institutional Review Board approved study, consecutive patients seen at 
the PD and Movement Disorders Centre of the National Neuroscience Institute (NNI) 
between April and December 2008 were recruited. The Centre co-located with a 
secondary hospital serves as a secondary and tertiary referral centre for both public 
and private sectors in Singapore and provides comprehensive care for PD patients at 
various stages of their disease. Patients meeting the National Institute of Neurological 
Disorders and Stroke criteria57 for the diagnosis of PD with follow-up of at least a 
year were included. All patients were evaluated in the on state. Patients who could not 
understand English or Chinese were excluded because the 8-item Parkinson’s Disease 
Questionnaire (PDQ-8) questionnaire was available in these languages only.4 Proxy 
assessment was employed for patients with severe cognitive impairment (as assessed 
by attending doctors).  
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Patients (or proxies) were interviewed by a single interviewer (YJZ) using 
their preferred choice of either English or Chinese standardized questionnaires 
including a financial burden questionnaire, two HRQoL questionnaires (PDQ-8 and 
EuroQoL (EQ-5D))3, 4 and the Beck Depression Inventory (BDI) questionnaire.140 If 
the interview could not be completed within one session for any reason, follow-up 
telephone interviews were conducted within one week.  
 
Data collection 
Clinical data were retrieved from patients’ medical records or the NNI 
Centre’s PD database which included patient demographic, date of diagnosis, duration 
of illness, co-morbid diseases, measures of disease severity by H&Y stage, the motor 
and ADL part of Unified Parkinson’s Disease Rating Scale (UPDRS), Schwab and 
England Activities of Daily Living (S&E ADL),141 Mini Mental State Examination 
(MMSE)58 and PD related pharmacotherapy (See Appendix II).  
 
PDQ-8, a brief version of the 39-item Parkinson’s Disease Questionnaire 
(PDQ-39), is widely and locally validated as a disease-specific HRQoL questionnaire 
for PD.64 It has a score range of 0 to 100. EQ-5D with a score range of -0.594 to 1, is 
one of the most commonly used generic preference-based HRQoL questionnaires that 
has also been validated locally (See Appendix III).142, 143 Cognitive evaluation was 
performed using the MMSE,
58
 with depression assessed by BDI (See Appendix 
IV).140  
 
The financial burden questionnaire (See Appendix V) collected data on direct 
medical, direct non-medical and indirect cost (namely, productivity loss and informal 
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care which is the care usually provided by patient’s family who will not be financially 
compensated144) during the past 12 months. A detailed breakdown of the cost 
components and their derivation is given below. The study was conducted using a 
prevalence-based bottom-up approach. The economic burden of PD was estimated by 
multiplying the annual total cost per patient estimated in this study by the prevalence 
rate of PD among Singaporeans aged >50 years and the number of Singaporeans aged 
>50 years. We further broke down cost into several components: direct medical cost, 
direct non-medical cost and indirect cost.  All cost was valued as 1USD=1.12SGD 
based on Purchasing Power Parity (PPP) published in economist in 2009.145 
 
Measurement of costs 
The interviewer-administered financial burden questionnaire captured cost 
related to direct medical cost, including those that were already captured by the 
hospital’s electronic administrative databases as well as those that were not currently 
captured, e.g. hospitalizations and specialist clinic visits at other hospitals, visits to 
general practitioners, ancillary treatment and nursing home care. In addition, the 
questionnaire also captures direct non-medical cost (such as alternative and 
complementary treatments, homecare, aids and home modification and transportation 
fee) and indirect cost. The derivation of these costs is detailed below. 
 
Direct medical cost 
Direct medical cost was computed using hospital databases and patient 
interviews. Direct medical cost available from hospital databases include cost related 
to hospitalization, outpatient visit, pharmacotherapy, ancillary treatment and 
emergency use. For these components, the unit charge (which would be the best 
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representative of the true cost to the institution as it is a public not-for-profit 
organization with charges based on cost recovery principle) and quantity (either 
number of episodes or number of units) used were retrieved from the database. For 
other direct medical cost components such as hospitalization in other hospitals, clinic 
visits to GPs and other hospitals, nursing home care and day care center which were 
not available in the hospital databases, they were obtained from the financial burden 
questionnaire administered to patients.  
 
Direct non-medical cost 
For direct non-medical cost, the unit cost and quantity used were also retrieved 
from the financial burden questionnaire. Home care was defined as care provided by 
professional domestic helpers, and the monthly cost was recorded as reported by the 
patients rather than imputed using market wage as the market wage depend on several 
factors such as years of working experience, etc.146  
 
Indirect cost 
Indirect cost which includes productivity loss (due to sick leave, early 
retirement, reduced salary and presenteeism at work), housekeeping services and 
provision of informal care by family members was estimated using the human capital 
approach. Patients or those family members aged younger than 63 years old were 
included in our estimates as the official retirement age in Singapore is 62 years old as 
our time-frame for estimation was over the past 12-month. Indirect cost also include 
cost for housekeeping services, and for this, the opportunity cost approach was taken 
instead of the human capital approach as the latter does not consider nonmarket 
activities. The monthly cost of housekeeping services was assumed to be the 
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published median monthly labor wage
51
 that the housekeeper would have earned if 
s/he had chosen to work.147 As the published data did not include individuals aged 60 
and above, we imputed the values for individuals aged 60 to 63 in our study using 
data for individuals aged 55 to 59.  
 
For working patients, the estimated productivity loss due to sick leave (both 
paid and unpaid) as a result of PD was calculated as their monthly income multiplied 
by duration of leave over a 12-month period as reported during the interview. Among 
patients who have retired prematurely due to PD, the estimate of productivity loss due 
to early retirement was taken as the product of their last drawn monthly wage and the 
number of months (maximum of 12 months) between their current age and 63. 
Furthermore, the estimated productivity loss due to salary reduction was calculated as 
the product of patients’ wage reduction due to PD by the number of months 
(maximum of 12 months) between their age when salary reduction incurred and 63. 
Additionally, using a visual analogue scale (VAS) ranging from 0 to 100%, patients 
also indicated the percentage of productivity loss due to presenteeism defined as 
potential productivity loss in both work and housekeeping services over the past 12 
months. Presenteeism at work and housekeeping were estimated by multiplying 12-
month wages and median labor wage with reported percentage of work loss 
respectively.  
 
Informal care was incurred when family members took temporary leave or 
changed to part-time employment to take care of the patients. For the former, the cost 
was calculated by multiplying the monthly wage of family members by the duration 
of their leave over the 12-month period; for the latter, the cost was calculated by 
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multiplying the reduced salary as a result of job change by the length of time since job 
change or 12 months, whichever is shorter. 
 
Statistical analyses 
The association between clinical, sociodemographic and HRQoL factors and 
cost and its components was studied using simple and multiple linear regression 
analyses with cost (total, direct medical, direct non-medical and indirect) as 
dependent variable and the relevant factors as independent variables. Due to the 
skewed nature of cost data, bootstrapped confidence intervals were computed using 
bias corrected accelerated approach with 1000 replications. In simple and multiple 
linear regression analyses, MMSE was categorized into <20 or >20 as a previous 
study showed that 20 is the optimal cut-off point for dementia in Singapore;59 whereas 
BDI was categorized into <16 or >16.148 Incidentally, S&E ADL scores were 
categorized into two groups: <70% and >70%, as a score of 70% indicated that the 
patient was not completely independent and required 3 to 4 times as long to perform 
some chores. Bootstrapping analyses were performed by STATA 10.0 for Windows 
(STATA Inc, Houston, TX); while all other analyses were performed with SPSS 17.0 




A total of 207 patients participated in our study. However, twelve patients 
were excluded (2 due to wrong diagnoses; 10 due to incomplete information.  Among 
those with incomplete information: 1 had missing demographic information, 1 had 
missing PDQ-8, and 8 had missing BDI), leaving 195 patients with complete data 
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included in the analysis (Table 5.1). The mean (SD) age of the patients was 68.2 (9.6) 
years. The majority of these patients was males (51.8%), ethnic Chinese (91.3%) and 
had at least primary school education (45.6%). The mean (SD) duration of PD was 6.1 
(4.1) years. The mean (SD) UPDRS motor and ADL score were 26.8 (14.4) and 9.9 
(6.1) points, respectively. The mean PDQ-8 summary index (PDQ-8SI) was 30.0 
(20.4). The majority of these participants had H&Y stage greater than or equal to 2.5 
(54.4%) and S&E ADL scores greater than 70% (76.9%). The results showed that our 
samples were a reasonable representation of the typical PD patients encountered in 
clinical practice.  
 
Table 5.1 Characteristics of study patients at baseline (n=195) 
Characteristics N (%) Median 
(Range) 
Age (years)  68.9 (44.1-
90.5) 
Males 101 (51.8)  
Education   
Primary education 89 (45.6)  
Secondary education 77 (39.5)  
Tertiary education 29 (14.9)  
Ethnicity   
Chinese 178 (91.3)  
Others (e.g. Indian or Malay) 17 (8.7)  
Marital status   
Married 142 (72.8)  
Others (e.g. Single or divorced) 53 (27.2)  
Housing type   
Public housing 154 (79.0)  
Private housing 41 (21.0)  
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Household size   
0-2 48 (24.6)  
3-4 100 (51.3)  
5-9 47 (24.1)  
Working status   
Employed 27 (13.8)  
Unemployed 168 (86.2)  
Duration of PD (years)  5.3 (0.9-19.4) 
0 to <5 93 (47.6%)  
< 5 to <10 70 (36.0%)  
< 10 to 15 21 (10.6%)  
> 15 11 (5.8%)  
H&Y stage   
1 15 (7.7)  
2 74 (37.9)  
2.5 31 (15.9)  
3 32 (16.4)  
4 28 (14.4)  
5 15 (7.7)  
UPDRS (Motor score)  24.0 (5.0-
68.0) 
UPDRS (ADL score)  9.0 (0.0-33.0) 
S&E ADL   
< 70% 45 (23.1)  
>70% 150 (76.9)  
Dyskinesias   
Yes 27 (13.8)  
No 168 (86.2)  
Wearing off   
Yes 73 (37.4)  
No 122 (62.6)  
MMSE   
< 20 50 (25.6)  
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>20 145 (74.4)  
BDI   
< 16 120 (61.5)  
>16 75 (38.5)  
Comorbidity   
0 56 (28.7)  
1 60 (30.8)  
2 43 (22.1)  
>3 36 (18.5)  
PDQ-8SI  28.1 (0.0-
90.6) 
EQ-5D utility score  0.6 (-0.4-1.0) 
EQ-5D VAS  65.0 (0.0-
100.0) 
SD: standard deviation  
H&Y stage: Hoehn & Yahr stage 
UPDRS: Unified Parkinson’s Disease Rating Scale 
ADL: Activities of Daily Living 
S&E ADL: Schwab and England Activities of Daily Living 
MMSE: Mini Mental State Examination 
BDI: Beck Depression Inventory 
PDQ-8SI: the 8-item Parkinson’s Disease Questionnaire Summary Index 
EQ-5D utility score: EuroQoL utility score 
EQ-5D VAS: EuroQoL Visual Analog Scales 
 
Cost-of illness of PD 
 Total annual cost of PD from a societal perspective was SGD11345 (USD PPP 
10129) per patient. Given that the prevalence of PD among Singaporeans aged >50 
years was 0.22-0.39%23 and the number of Singaporeans aged >50 years was 1.04 
million, the total annual economic burden to Singapore would be between SGD26-46 
(USD PPP 23-41) million, approximately 0.7-1.2% of Singapore’s total healthcare 
budget in 2009.
149
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 The distribution of individual cost components is shown in Table 4.2. Of the 
annual total cost, direct cost accounted for 38.5% and indirect cost 61.5%. In direct 
medical cost, the top three cost drivers were pharmacotherapy (50.4%), 
hospitalization (20.5%) and nursing home care (9.4%). With regards to 
pharmacotherapy, the top three cost contributors for antiparkinsonian drug treatments 
were levodopa (43%), dopamine agonists (32%) and catechol-O-methyl transferase 
(COMT) inhibitors (21%). Levodopa was received by 92.8%, dopamine agonists by 
37.4% and monoamine oxidase B (MAO-B) inhibitors by 22.1% of our patients 
respectively. In addition, almost two thirds (64.1%) of our patients received others 
drugs to treat non-motor symptoms of PD e.g. depression, anxiety, constipation, etc. 
With regards to hospitalization, the top two causes for hospitalization were falls due 
to accident or psychiatric problem. For direct non-medical cost, the top three cost 
drivers were home care (76.1%), complementary treatment (17.3%) and transportation 
(4.6%).  
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Table 5.2 Breakdown of cost incurred by PD patients over a 12-month period  
 Mean (SD) 
SGD 
Median (Interquartile range ) 
SGD 
Percentage 
of total cost 
95% CI 
Direct cost     
Direct medical cost 2550 (3946) 1137 (740-2278) 22.5 2072-3166 
Hospitalization (n=15) 522 (2538) 0 (0-0) 4.6 235-998 
Outpatient visit (n=195) 236 (167) 190 (165-235) 2.1 219-265 
Pharmacotherapy (n=195) 1285 (1405) 759 (471-1619) 11.3 1117-1507 
Nursing home care (n=5) 240 (1867) 0 (0-0) 2.1 68-710 
Day care center (n=5) 199 (1361) 0 (0-0) 1.8 66-484 
Ancillary treatment (n=46) 
(e.g. physiotherapy or speech therapy) 
48 (117) 0 (0-0) 0.4 34-69 
Emergency use (n=18) 20 (77) 0 (0-0) 0.2 10-33 
Direct non-medical  cost 1816 (2664) 210 (35-3061) 16.0 1494-2262 
Home care (n=51) 1382 (2525) 0 (0-2580) 12.2 1058-1746 
Aids & home modification (n=29) 35 (135) 0 (0-0) 0.3 21-62 
Complementary treatment (n=69) 
(e.g. massage, acupuncture therapy etc.) 
315 (780) 0 (0-200) 2.8 229-452 
Transportation fee (n=193) 84 (132) 51 (18-91) 0.7 68-107 
Total direct cost 4366 (4906) 2147 (913-6496) 38.5 3741-5128 
Indirect cost     
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Productivity losses (n=49) 6832 (24681) 0 (0-888) 60.2 4426-12301 
Informal care (n=56) 147 (614) 0 (0-150) 1.3 95-313 
Total indirect cost 6979 (24654) 0 (0-2000) 61.5 4683-12460 
Total cost (n=195) 11345 (25081) 4805 (1131-11367) 100.0 8824-16523 
N: number of users 
95% CI: 95% confidence interval by bias corrected accelerated bootstrapping approach 
1 USD = 1.12 SGD based on Purchasing Power Parity (PPP) published in economics in 2009
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Majority of patients had retired (n=168, 86.2%) with only 27 patients (13.8%) 
still working. Among the working participants, 5 (18.5%) had to be temporarily 
absent from work or had salary reduction due to PD. Of retirees, 19 (11.3%) had 
retired early due to PD. Productivity loss caused by sick leave, early retirement and 
reduced salary due to PD amounted to SGD3094 (USD PPP 2763) per year. Of 27 
working patients, 16 (59.3%) had incurred presenteeism at work; whereas of 39 
patients who were housekeepers, 36 (92.3%) reported reduced productivity. 
Productivity loss as a result of presenteeism at work and housekeeping services were 
SGD1095 (USD PPP 978) and SGD2643 (USD PPP 2360) respectively. Furthermore, 
56 patients (28.7%) required their family members to take temporary leave or change 
to part-time job to provide informal care of them which amounted to SGD147 (USD 
PPP 131).  
 
Factors affecting cost 
In simple linear regression analysis (Table 4.3), higher education, employed 
status, younger age and longer duration of PD were associated with higher total cost.. 
The detailed associations between factors and individual cost components i.e. direct 
medical, direct non-medical and indirect cost were summarized in Table 4.3. 
 
In multiple linear regression analysis (Table 3), higher education, younger age 
and longer disease duration remained associated with higher total cost. These cost 
determinants accounted for 26% of the variability in total cost. Living in private 
housing, higher UPDRS motor scores and lower EQ-5D utility (poorer HRQoL) 
scores remained associated with direct medical cost , while larger households, older 
age, longer disease duration and higher PDQ-8SI (poorer HRQoL) scores remained 
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associated with direct non-medical cost. Interestingly, after adjusting for potential 
confounders, the factors associated with both direct medical and non-medical cost 
were no longer common. The variables (higher education and younger age) associated 
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Table 5.3 Simple and multiple linear regression analysis: effect size of factors on cost incurred by PD patients over a 12-month period 
  
Dependent variable  
Total cost Direct medical cost Direct nonmedical cost Indirect cost 
SLR MLR SLR MLR SLR MLR SLR MLR Independent variable 
Effect size Effect size Effect size Effect size Effect size Effect size Effect size Effect size 
Gender 
(Female) 
-5267.8 N/A -81.0 N/A 590.4 N/A -5777.1 N/A 
Ethnicity 
(Non-Chinese) 
756.8 N/A -156.4 N/A -638.0 N/A 1551.2 N/A 
Marital status 
(Not-married) 
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Working status 
(unemployed) 
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H&Y stage (≥ 2.5) 30.1 N/A 1468.8** -1478.5 1474.5*** 56.9 -2913.3 N/A 
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3
rd
 quartile: 10-13 













S&E ADL (>70%) 1169.7 N/A -2372.9*** -219.0 -2534.3*** -890.1 6077.0 N/A 
Dyskinesias 
(without dyskinesias) 
3067.8 N/A -505.9 N/A -997.9 N/A 4571.6 N/A 
Wearing off 
(without wearing off) 
7.7 N/A -1336.0* -555.8 -1016.4* -449.7 2360.1 N/A 
MMSE (>20) 4233.5 N/A -1724.4** -21.3 -2057.8*** -662.1 8015.8* -280.1 








































PDQ-8SI 121.5 N/A 39.0** -38.3 45.8*** 24.8* 36.8 N/A 
EQ-5D utility score -840.9 N/A -3816.1*** -3373.1* -2897.1*** 212.9 5872.3 N/A 
EQ-5D VAS -88.9 N/A -35.7* -9.8 -34.3** -3.0 -19.0 N/A 
*p< 0.05; **p<0.01, ***p<0.001 (two-tailed). 
For the categorical variables, the first group was treated as reference group 
SLR: Simple linear regression  
MLR: Multiple linear regression 
H&Y stage: Hoehn & Yahr stage 
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UPDRS: Unified Parkinson’s Disease Rating Scale 
ADL: Activities of Daily Living 
S&E ADL: Schwab and England Activities of Daily Living 
MMSE: Mini Mental State Examination 
BDI: Beck Depression Inventory 
PDQ-8SI: the 8-item Parkinson’s Disease Questionnaire Summary Index 
EQ-5D utility score: EuroQoL utility score 
EQ-5D VAS: EuroQoL Visual Analog Scales 
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DISCUSSION 
 In this study, we found the economic burden in a cohort of PD patients in 
Singapore to be SGD11345 (USD PPP 10129) per patient over a 12-month period 
(direct cost: 38.5% and indirect cost: 61.5%).  
 
In general, based on PPP, the direct medical cost estimated in our study (mean 
= SGD2550 (USD PPP 2277)) was much higher than that reported in China136 
(equivalent to SGD1543 (USD PPP 1378)), India137 (equivalent to SGD228 (USD 
PPP 204)); but was comparable to those reported in Eastern European countries such 
as Russia131 (SGD1916 (USD PPP 1711)) and Czech130 (SGD2262 (USD PPP 2020)) 
and lower than that reported in other Western countries (with cost ranging from 
SGD3004 (USD PPP 2682) to SGD11591(USD PPP 10349)).126, 129, 133  This 
difference in cost among countries could be explained by varying financing 
mechanisms, cost structure and efficiency of different health care systems in different 
jurisdictions.  
 
Although the absolute values of direct medical cost varied among countries, 
the cost drivers appeared similar. In our study, pharmacotherapy was the main cost 
driver, responsible for 50.4% of direct medical cost, which was similar to those 
reported elsewhere (ranging from 44.3% to 58.1%).129-131, 133, 135, 136 Furthermore, it 
was found in our study that despite being cheaper than dopamine agonist, levodopa 
actually contributed more to pharmacotherapy cost due to the very high percentage of 
patients on levodopa (93%). Hospitalization was the second major cost driver, 
accounting for 20.5% of direct medical cost, again similar to those reported in three 
previous studies (ranging from 16.2% to 27.9%).129, 130, 133 Meanwhile, it is worth 
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noting that 15 out of 195 subjects’ hospitalization cost accounted for 5% of the total 
cost. These findings suggested that strategies to optimize pharmacotherapy and 
prevent or reduce avoidable hospitalizations would possibly reduce the economic 
burden of PD. In our study, we should clearly work towards preventing falls and 
recurrent falls among PD patients as this was the major cause of hospitalization. Other 
causes of hospitalization were pneumonia because of immobility, postural 
hypotension and cognitive impairment. 
 
The major contributor to direct non-medical cost contributor was home care, 
with almost a quarter of our patients need to be taken care of by domestic helpers and 
amounted to SGD1382 (USD PPP 1234) per year. This is nearly 76.1 % of direct non-
medical cost highlighting the heavy burden to the family as this is usually not 
subsidized by government nor covered by health insurance. 
 
Similar to direct cost, indirect cost in our study amounted to SGD6832 (USD 
PPP 6100) annually and based on PPP, were higher than some Eastern European 
countries, such as Russia (SGD1852 (USD PPP 1654)) and Czech (SGD4652 (USD 
PPP 4154)) and comparable to some Western countries such as Sweden (SGD5474 
(USD PPP 4888)), Finland (SGD6066 (USD PPP 5416)) and Germany (SGD6849 
(USD PPP 6115)).129-133 There are several possible explanations for the difference. 
First, gross national income per capita was different in the various countries.
74
 Since 
lost income is an important contributor to computation of indirect cost, income 
variation across various countries could account for variation in indirect cost. Second, 
the mean age of diagnosis for our patients was close to the official retirement age of 
62 in Singapore. Hence, this could explain the lower productivity loss experienced by 
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our patients compared to other studies which have a retirement age of 65 years 
officially. Third, methodology for evaluating cost of informal care cost varied across 
the studies. In our study, cost of informal care was defined as loss resulting from 
absence from work or changes in employment status incurred by the caregivers in 
order to provide care for PD patients.  The cost of informal care in our study 
amounted to only SGD147 (USD PPP 131) annually, which was extremely low 
compared to other published studies (SGD2033 to SGD8012 (USD PPP 1815 to USD 
PPP 7154)).132, 134 One possible reason was that majority of these patients were taken 
care by domestic helpers or by spouses who were near or already retired due to our 
earlier retirement age.  
 
Both younger age and longer disease duration were found to be associated 
with higher total costs. At first glance, this appeared inconsistent. However, the 
association became clearer when we broke down the total costs into its individual 
components. Younger age was associated with higher indirect cost while longer 
disease duration was associated with direct medical and non-medical costs.  
 
We compared our findings with published studies and found that our finding 
of younger age130, 131 but not gender131 and presence of depression (i.e. higher BDI 
scores in our study)130, 131 being associated with higher total cost was similar to other 
studies. Similar comparison for the impact of disease duration on total costs could not 
be determined due to the paucity of studies that evaluated this factor. Interestingly, 
between the two measures of disease severity, UPDRS motor scores but not H&Y 
stage was significantly associated with direct medical cost in our study. This finding 
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is similar to one recent study which found that higher UPDRS was associated with not 
only total cost but also direct cost.135  
 
Contrary to one published study, worse HRQoL131 was not significantly 
associated with total cost in our study. However, in our study, the disease-specific 
PDQ-8 scores were associated with direct non-medical cost while the generic EQ-5D 
scores were associated with direct medical cost although both were not associated 
with total cost. 
 
To the best of our knowledge, this is the first COI study for PD patients in 
Southeast Asia, as well as one of the few studies to provide a thorough investigation 
of clinical, sociodemographic and HRQoL factors associated with PD cost. 
Furthermore, our findings are likely to be robust with high concordance between 
patient-reported data and data generated by the hospital’s business office.  
 
Nevertheless, we acknowledged that there are limitations with our study. First, 
we did not include the cost of premature death. Second, the cross-sectional design 
precludes our ability to draw causal inferences among cost and clinical, 
sociodemographic and HRQoL factors. Longitudinal studies are warranted in the 
future. Third, the exclusion of non-English and non-Chinese speaking patients from 
our study has limited the generalizability to the general PD population in Singapore. 
However, this was a necessary compromise as the PDQ-8 questionnaire was not 
available in Malay and Tamil and known discrepancies between proxy- and self-
reported HRQoL150 discourage our use of proxy assessment for non-English or non-
Chinese speaking patients. We seek to develop the Malay and Tamil translations of 
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the PDQ-8 questionnaire in the near future and update this cost analysis. Fourth, 
generalizability of the findings of this study to other sociocultural context remains to 
be determined. Fifth, using a length of 12 months in the financial burden 
questionnaire may introduce recall bias. However, funding constrain limits our ability 
to conduct multiple follow-ups at shorter intervals. In addition, extrapolating data 
from a shorter recall period (e.g. 3-months) by simple multiplication (e.g. factor of 4) 
would also introduce measurement bias as resource consumption is not constant over 
a 12-month period. For example, if the time of assessment coincided with a 
hospitalization episode, then this would lead to an overestimation of the true cost. 
Nonetheless, it was reassuring that a high concordance between patient-reported data 
and hospital-generated data was observed in our study. Sixth, although we did not 
explicitly exclude patients who are likely to have received expensive treatments such 
as deep brain stimulation, there were no patients using any of these expensive 
treatments. Hence, this study may represent an underestimation of the economic 
burden of PD.       
 
In conclusion, this study shows that PD exerts a considerable burden on 
patients, health care system and society at large in Singapore to be SGD11345 (USD 
PPP 10129) per patient over a 12-month period. As the largest share of the cost is due 
to productivity loss, treatments and health care programmes with potential for 
returning patients to higher productivity are urgently needed. Further research is 
needed on the investigation of life-time cost in PD which enables the evaluation of 
long-term clinical and economic effectiveness of alternative interventions. 
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INTRODUCTION 
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder 
primarily affecting the elderly. As a result of an aging population, PD is becoming a 
relatively common disease among the elderly in many countries throughout the world, 
with prevalence rates between 18 and 418 per 100,000 worldwide.18 According to a 
recent study, the number of PD patients is projected to double in the next 25 years.
125 
 
Given the increasing prevalence of PD and its significant impact on the 
functional status and Health Related Quality of Life (HRQoL) of PD patients,49, 53 it is 
conceivable that PD imposes a significant economic burden on society. Several 
studies have pointed out that PD exerts a considerable burden on patients, the health 
care system and society at large.126, 129, 136, 151, 152 However, all existing studies were 
cross-sectional in nature, estimating the economic burden of PD over 6-month or 1-
year periods. Given that PD is a progressive disease, the economic burden of PD is 
likely to vary with disease course. For example, in the early stages of the disease, 
management of PD would usually involve fewer and less expensive medications. 
However, as the disease progresses, the number of medications is likely to increase, 
both for managing PD symptoms as well as the adverse effects associated with the use 
of anti-parkinsonism medications e.g. motor complications associated with levodopa 
therapy. Besides direct medical cost, the progressive nature of PD would also impact 
on the indirect cost of PD but the consequences are less clear. This is because as the 
non-motor symptoms associated with PD such as autonomic dysfunction, cognitive 
and neurobehavioral problems, sensory and sleep disturbances increase over time and 
reduce patient’s productivity, more of these patients also dropped out of the 
workforce as they have reached retirement age. To the best of our knowledge, no 
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studies have evaluated life-time economic burden of PD as well as the association 
between disease course and life-time economic burden. Given the progressive nature 
of PD, taking a snapshot of the economic burden of PD may be misleading. A better 
understanding of the association between disease course and economic burden would 
be helpful in informing resource allocation. The development of an economic model 
based on a life-time perspective would also be helpful for evaluating competing health 
care technologies that may exert differential effectiveness over the disease course.  
 
We aimed to estimate the life-time economic burden of PD in Singapore, a 
multi-ethnic South-East Asia country comprising 74% Chinese, 14% Malays and 9% 
Indians,
44
 at 5-yearly interval (5-, 10-, 15-year and life time) using Markov cohort 
simulation. Markov cohort simulation is a widely used decision analytic modeling 
tool for performing economic evaluation that informs medical decision making under 
conditions of uncertainty.153 It is particularly useful for modeling chronic medical 
conditions as it can accommodate the complex analyses of multiple possible 
consequences over time. A breakdown of the total cost into the constituent 
components will be provided at each 5-year interval to better inform the cost 
determinants in the economic burden of PD. 
 
METHODS 
Subjects and data collection 
Details of subjects, study design and data collection have been described in 
Chapter 5.154 Information that is relevant to this study are summarized here. In this 
Institutional Review Board approved study, consecutive patients seen at the PD and 
Movement Disorders Centre of the National Neuroscience Institute (NNI), a 
Chapter 6. Estimating the life-time economic burden in PD                    Zhao Yingjiao 
  85                                                                                                
secondary and tertiary referral centre for both public and private sectors in Singapore, 
between April and December 2008 were recruited. Patients meeting the National 
Institute of Neurological Disorders and Stroke criteria57 for the diagnosis of 
Parkinson’s disease with follow-up of at least a year were included. All patients were 
evaluated in the on state. Patients who could not understand English or Chinese were 
excluded because the 8-item Parkinson’s Disease Questionnaire (PDQ-8) 
questionnaire for assessing Parkinson-specific HRQoL was available in these 
languages only.4 Further information on the PDQ-8 was not provided in this study as 
data from the PDQ-8 were not incorporated in this analysis. 
 
Clinical data were retrieved from patients’ medical records or the NNI 
Centre’s PD database which included patient demographic, date of diagnosis, duration 
of illness, co-morbid diseases, measures of disease severity by H&Y stage, the motor 
and ADL part of Unified Parkinson’s Disease Rating Scale (UPDRS), Schwab and 
England Activities of Daily Living (S&E ADL),141 Mini Mental State Examination 
(MMSE),
58
 Beck’s Depression Inventory (BDI)
140
 and PD related pharmacotherapy. 
Health utilities was assessed with the widely used EuroQoL 5 dimension (EQ-5D), 
which has a score range of -0.594 to 1 that has previously demonstrated good 
measurement properties in several local studies.142, 143  
 
Costs were estimated using a bottom-up approach using a combination of 
hospital administrative databases and patient interviews using a financial burden 
questionnaire. A detailed breakdown of the cost components and their derivation was 
previously reported.154 Direct medical cost was computed using hospital databases 
(hospitalization, outpatient visit, pharmacotherapy, ancillary treatment and emergency 
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services) and patient interviews (hospitalization in other hospitals, clinic visits to GPs 
and other hospitals, nursing home care and day care center). Direct non-medical cost 
such as home care was captured using patient interviews. It should be noted that home 
care was defined as care provided by domestic helpers. Indirect cost which comprises 
productivity loss (due to sick leave, reduced salary, early retirement, and presenteeism 
at work) and informal care was estimated using the human capital approach, with an 
exception in the estimate of productivity losses by home makers, which was estimated 
using the opportunity cost approach. Presenteeism at work, measured using a 0% to 
100% visual analogue scale (VAS), was defined as potential productivity loss in both 
work and housekeeping services over the past 12 months. Informal care refers to 
productivity losses incurred when family members took short-term leave or gave up 
full-time employment to take care of the patients. All cost was valued as 
1USD=1.12SGD based on Purchasing Power Parity (PPP) published in The 
Economist in 2009.145 
 
Model structure 
As we sought to characterize the experience of the average patient from a 
population sharing the same characteristics, we employed the Markov cohort 
simulation model to compute the expected costs and benefits associated with PD. The 
Markov cohort model comprised of five mutually exclusive health states defined by 
modified Hohn and Yahr stages and the state of being dead and was constructed using 
TreeAge Pro 2009 (TreeAge Software, Williamstown, MA) (Figure 6.1). A cohort of 
1000 patients started the cycle in H&Y stage 1. The cycle length was defined as one 
year because the transition from one H&Y stage to the next or death rarely occurs 
more than once a year. The probabilities of moving to other states or remaining in the 
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same states were defined by a transition probabilities matrix (see next section). Each 
state except dead is associated with specific costs and benefits. As PD is a progressive 
neurodegenerative disease, patients in our study were assumed to progress from one 
Markov state to the next state or dead over the course of the disease without skipping 
or regressing (i.e. patients cannot experience improvement in health). The model 
followed up the patients until they died or when they on average reached the age of 81 
years which is the average life expectancy in Singapore.155 The evaluation took a 
societal perspective, thus incorporating direct medical, direct non-medical and 
indirect costs. Cost for each H&Y stage was calculated by taking the average cost 
incurred by each patient at that specific H&Y stage. Half cycle correction was made 
on the cost parameters in the model.  
 
Figure 6.1 State transition diagram for Markov model 
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Transition probabilities 
The rate of progression from one H&Y stage to the next calculated using 
Kaplan Meier survival analysis was previously reported in Chapter 4.156 The reported 
rate of progression was converted to transition probabilities using the following 
formula: P= 1-exp(-rt) where P is the transition probability, r is the reciprocal of time 
taken to progress  through various H&Y stages and t is the cycle length.
157
 The 
mortality for patients at various H&Y stages was imputed using all-cause mortality 
data provided by the Ministry of Health Singapore.    
 
Sensitivity analysis 
Probabilistic sensitivity analysis (PSA) with 1000 sampling was performed on 
the transition probabilities and cost parameters i.e. direct medical, direct non-medical 
and indirect cost as well as their cost drivers to assess the impact of changing those 
components in the model.  In PSA, uncertainty in transition probability and cost 
parameters were represented by beta and gamma distribution, respectively158.   
 
Discount Rate 
Both cost and utility were discounted at 5% as suggested for economic 
evaluations by the British Medical Journal.159 
 
Results 
 Total cost of PD from a societal perspective was SGD 61206 (USD PPP 
54648) per patient over a life-time period. The distribution of individual cost 
components incurred by PD over time is shown in Table 6.1. Of the 5-year, 10-year 
and 15-year cost, direct medical and non-medical cost accounted for 16.4%, 17.6%, 
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18.5% and 10.9%, 12.0%, 12.6% respectively; whereas indirect cost accounted for 
72.7%, 70.4% and 68.8% respectively. Of the life time cost, direct medical, non-
medical and indirect cost accounted for 18.7%, 12.8% and 68.5% respectively. Of 
direct medical cost, the higher cost over time was accounted by increasing uses of 
hospitalization, nursing home care and day care center. Of direct non-medical cost, 
the higher cost over time was contributed by increasing needs of home care. The 
decreasing cost in productivity losses led to lower indirect cost over time, although 
the cost of informal care was slightly increasing. In direct medical cost, the top three 
cost determinants were always pharmacotherapy, hospitalization and outpatient visit; 
whereas in direct non-medical cost, the top three cost determinants were always home 
care, complementary treatment and transportation irrespective of time period. 
Productivity loss accounted for not only the largest share of indirect cost but also of 
total life time economic burden imposed by PD. 
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Table 6.1 Breakdown of cost incurred by a cohort of PD patients (mean age=66) over a 5-year, 10-year, 15-year and life time period  
 
 5-year 10-year 15-year Life time 
 Mean % of 
total cost 
Mean % of 
total cost 
Mean % of 
total cost 
Mean % of 
total cost 
Direct cost         
Direct medical cost 6419 16.4 9956 17.6 11222 18.5 11467 18.7 
Hospitalization 764 1.9 1485 2.6 1776 2.9 1834 3.0 
Outpatient visit 912 2.3 1250 2.2 1340 2.2 1355 2.2 
Pharmacotherapy 4550 11.6 6413 11.4 6877 11.4 6951 11.4 
Nursing home care 34 0.1 318 0.6 580 1.0 646 1.1 
Day care center 33 0.1 265 0.5 394 0.7 420 0.7 
Ancillary treatment 
(e.g. physiotherapy or speech therapy) 
106 0.3 178 0.3 199 0.3 202 0.3 
Emergency use 19 0.0 47 0.1 57 0.1 58 0.1 
Direct non-medical  cost 4276 10.9 6771 12.0 7655 12.6 7821 12.8 
Home care 2608 6.6 4456 7.9 5191 8.6 5333 8.7 
Aids & home modification 31 0.1 79 0.1 98 0.2 102 0.2 
Complementary treatment 
(e.g. massage, acupuncture therapy etc.) 
1371 3.5 1844 3.3 1941 3.2 1995 3.3 
Transportation fee 266 0.7 392 0.7 425 0.7 431 0.7 
Total direct cost 10699 27.3 16732 29.6 18884 31.2 19294 31.5 
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Indirect cost         
Productivity losses 28377 72.3 39385 69.7 41219 68.1 41437 67.7 
Informal care 160 0.4 356 0.6 458 0.8 480 0.8 
Total indirect cost 28538 72.7 39741 70.4 41677 68.8 41917 68.5 
Total cost 39232 100.0 56468 100.0 60555 100.0 61206 100.0 
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Cost components and unit cost per H&Y stage contributors to the life-time 
cost was summarized in Table 6.2. As we can see, the 12-month total cost is highest 
in H&Y stage 2.5 and lowest in H&Y stage 1.  
 
Transition probabilities imputed by the time to transition from one stage to the 
next or death was shown in Table 6.3. For example, the probability for remaining at 
commencing H&Y stage 1, transiting from H&Y stage 1 to 2 or death was 0.549 and 
0.451 respectively. 
 
PSA was performed on the main probability and cost assumptions in order to 
test robustness of results in the model. In PSA, estimation of life time cost was highly 
sensitive to variation in productivity loss and indirect cost with mean (range) life time 
cost being SGD62290 (19773 to 820303) (USD PPP 55616 (17654 to 732413)) and 
SGD64641 (17227 to 761929) (USD PPP 36654 (20964 to 930388)), respectively 
(Table 6.4).  
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Table 6.2 Cost components for each H&Y stage 
 H&Y stage 
 1 (N=15) 2 (N=75) 2.5 (N=30) 3 (N=32) 4 (N=28) 5 (N=15) 
Direct cost       
Direct medical cost 1323 1838 1754 2723 3389 6994 
Hospitalization 0 301 354 572 873 1725 
Outpatient visit 272 206 227 268 220 325 
Pharmacotherapy 1039 1296 1017 1634 1313 1231 
Nursing home care 0 0 81 0 0 2946 
Day care center 0 0 0 120 894 667 
Ancillary treatment 
(e.g. physiotherapy or speech therapy) 
12 30 63 85 43 70 
Emergency use 0 5 12 44 46 30 
Direct non-medical  cost 1051 1007 1447 1990 3303 4187 
Home care 656 572 848 1641 2902 3829 
Aids & home modification 0 7 33 42 94 88 
Complementary treatment 
(e.g. massage, acupuncture therapy etc.) 
337 366 421 226 236 154 
Transportation fee 58 62 145 81 71 116 
Total direct cost 2374 2847 3202 4713 6692 11181 
Indirect cost       
Chapter 6. Estimating the life-time economic burden in PD                                                                                                       Zhao Yingjiao                                                                                   
  94                                                                                                
Productivity losses 3931 9458 12183 5017 1254 0 
Informal care 13 41 133 100 224 792 
Total indirect cost 3944 9499 12316 5117 1478 792 
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Table 6.3 Transition probability from one H&Y stage to the next or death during 1 
year period 
 
 Probability of entering H&Y stage 
Commencing H&Y stage 1 2 2.5 3 4 5 Death 
1 0.549 0.451 Nil Nil Nil Nil 0.000 
2 Nil 0.675 0.173 Nil Nil Nil 0.152 
2.5 Nil Nil 0.452 0.381 Nil Nil 0.167 
3 Nil Nil Nil 0.402 0.394 Nil 0.204 
4 Nil Nil Nil Nil 0.415 0.369 0.216 
5 Nil Nil Nil Nil Nil 0.575 0.425 
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Table 6.4 Probabilistic sensitivity analysis for cost and transition probability 
parameters 
 Life-time Cost (Second-order Monte Carlo simulation) 
Parameter (univariate) Mean (SD) Minimum Maximum 
Hospitalization 61928 (16623) 59376 517166 
Pharmacotherapy 61166 (4544) 54877 90398 
Home care 61609 (8111) 56050 210602 
Productivity loss 62290 (80068) 19773 820303 
Direct medical cost 61467 (10360) 50962 217817 
Direct non-medical cost 61425 (7477) 53929 176727 
Indirect cost 64641 (80778) 19294 853361 
Total cost 61534 (68693) 4707 523229 
Transition probability 61094 (1182) 57408 64777 
Parameter (multivariate)    
Total cost and transition 
probability 
62524 (74394) 3572 616325 
*SD: standard deviation 
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Discussion 
 In this study, we found the total life-time economic burden in a cohort of 
Singaporean PD patients to be SGD 61206 (USD PPP 54648) per patient (direct 
medical, non-medical and indirect cost: 18.7%, 12.8% and 68.5%).  
 
 Following up PD patients over a life-time period, we found that direct medical 
and non-medical cost was increasing; whereas indirect cost was decreasing over time. 
The determinants for higher direct medical and non-medical cost over time were 
hospitalization, nursing home care and home care respectively. These findings 
confirmed clinical observations that patients were hospitalized more often and had 
increasing use of nursing home care or employed domestic helper when patients’ 
disease progressed over time. In contrast, the determinant for lower indirect cost over-
time was productivity loss. This finding could be explained by the fact that more 
patients reached 62 years old (official retirement age in Singapore) over time or exited 
the model due to death.  
 
The direct comparison of life-time cost determinants could not be determined 
due to the paucity of studies that evaluated the association between these factors and 
life-time cost of PD. However, in our study, we found that pharmacotherapy was the 
main cost determinant, responsible for 60.6% of direct medical cost, which was 
similar to one previous study that aimed to report annual month cost of PD 
(58.1%).152 Additionally, hospitalization was the second major cost determinant, 
accounting for 16.0% of direct medical cost, again similar to that reported in one 
previous study with the aims to estimate annual economic burden of PD (16.2%) 133 
These findings suggested that strategies to optimize pharmacotherapy and prevent or 
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reduce avoidable hospitalizations would possibly reduce the life time economic 
burden of PD. As reported in our study, falls and recurrent falls was the major cause 
of hospitalization, we should clearly attempt to prevent falls and recurrent falls among 
our PD patients.  
 
The major contributor to direct non-medical life-time cost was home care 
(68.2%), with almost a quarter of our patients need to be taken care of by domestic 
helpers and amounted to SGD5333 (USD PPP 4762) over life-time period. The 
reduction of government levy on foreign domestic helper would help to relief the life-
time economic burden of PD.  
 
Productivity loss accounted for the largest share of not only indirect but also 
total life-time economic burden of PD and amounted to SGD41437 (USD PPP 36997). 
As assessed by PSA, estimation of life time cost was highly sensitive to variation in 
productivity loss and indirect cost. This would imply that reduction in productivity 
loss or indirect cost would contribute significantly to alleviate the economic burden of 
PD. Hence, treatments and health care programmes i.e. physiotherapy, occupational 
therapies etc. with potential for returning patients to higher productivity are urgently 
needed in order to reduce the economic burden of PD. Although the proportion of 
informal care was slightly increasing over time, it only amounted to SGD480 (USD 
PPP 429) for life-time period. One possible explanation was that majority of our 
patients were taken care by domestic helpers or by spouses who were near or already 
retired. 
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Our study has some limitations. First, due to lack of data, in the model we did 
not allow patients to skip or improve in disease stages. Second, we excluded the cost 
of mortality because of limited data. Third, model calibration was not performed due 
to paucity of real observational data or other model studies in terms of life time cost in 
PD. Fourth, generalizability of the findings of this study to other socio-cultural 
context remains to be determined. Fifth, there were no patients using any of expensive 
treatments e.g. deep brain stimulation in base case of the model. Hence, this study 
may represent an underestimation of the economic burden of PD.     
 
In conclusion, PD exerts a substantial burden to the society with a total life 
time cost amounted SGD61206 (USD PPP 54648) in Singapore. The life-time cost is 
predominated by productivity loss, irrespective of disease course or duration. This 
indicates that treatments or health programmes which potentially maintain patients’ 
higher productivity are urgently needed. 








Selegiline Use is Associated with a Slower Progression in 
Early Parkinson’s Disease as Evaluated by Hoehn and Yahr 
Stage Transition Times 
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INTRODUCTION                      
Parkinson’s disease (PD) is a chronic neurodegenerative disorder that 
relentlessly progresses over the course of time.  We had previously estimated that PD 
patients take 13 years to transit from modified Hoehn and Yahr (H&Y) stage 1 to 5 
with an estimated transition time of 2 to 5 years between each stage.160  In an attempt 
to halt the progress of the disease, much research has been devoted to identifying 
therapies that could modify or slow the course of PD.  Of the many treatment options 
investigated, the most promising has been the use of monoamine oxidase type B 
(MAO-B) as a possible disease modifying drug.  The ADAGIO study concluded that 
early treatment with rasagiline at a dose of 1mg per day provided benefits that were 
consistent with a possible disease-modifying effect.
38
   
 
Rasagiline is however not widely available globally.  It use has so far been 
primarily restricted to North America and Europe with many other regions of the 
world depending on selegiline for MAO-B inhibition.  The results of a number of 
clinical trials suggested that the use of selegiline in early PD may slow disease 
progression and improve long-term outcomes.39-41  These studies used either the onset 
of motor complications or Unified Parkinson Disease Rating Scale (UPDRS) scores 
as surrogate markers of disease progression.  We undertook this study to evaluate the 
association between selegiline use and PD progression in a clinical sample using a 
novel approach of evaluating the time taken for patients with and without selegiline 
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Clinical and sociodemographic data were retrieved from the Movement 
Disorder Database of the PD and Movement Disorders Centre of the National 
Neuroscience Institute, Singapore.160  The inclusion criteria for the extraction of 
patients from the database have been provided in detail in Chapter 4.160  In this study, 
an additional inclusion criterion was the presence of complete PD drug information.  
Data on gender, ethnicity, age at diagnosis, duration of disease, modified H&Y scores, 
UPDRS motor scores and pharmacotherapies including levodopa, dopamine agonist, 
selegiline, catechol-O-methyl transferase (COMT) inhibitors, anti-cholinergics, and 
amantadine were obtained from the database. Duration of treatment was measured 
from the onset of treatment until the transition or censored event.   
 
Statistical Analyses 
Cox regression analysis was used to examine the effect of selegiline on H&Y 
transition times by using a similar approach to what has been reported previously in  
Chapter 4.
160
 The analyses were performed in two steps. First, univariate analyses 
were conducted to evaluate the association of individual factors on PD progression. 
Second, those factors that were statistically significant (p<0.05) in univariate analyses 
were evaluated collectively in a multivariate model. The sociodemographic and 
clinical variables evaluated in univariate analysis included gender, ethnicity, age at 
diagnosis, duration of disease, UPDRS scores and pharmacotherapies.   
 
 Age-at-diagnosis, duration of PD, and UPDRS motor scores were coded into 
four groups using the quartiles’ approach. Due to the small number of Malay, Indian 
and participants of other ethnicities, we categorized ethnicity into Chinese and non-
Chinese.  We categorized duration of selegiline therapy into three groups: non-
selegiline treated, selegiline-treated (< 3 years), and selegiline-treated (≥ 3 years) 
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patients. Other pharmacotherapy variables were dichotomized (Table 1).  All data 
analyses were performed with SPSS 17.0 for Windows (SPSS Inc, Chicago, IL).  In 
SPSS, the first category of each categorical variable was regarded as the reference 
group.  Statistical significance was set at P < 0.05. 
 
RESULTS 
687 patients who met inclusion criteria were included in this study.  The 
detailed baseline characteristics of participants who entered each stage have been 
summarized previously in Chapter 4.160  In univariate Cox regression analysis, 
selegiline-treated patients (≥ 3 years) had longer transition times from stage 2 to 2.5 
and 2.5 to 3 compared to non-selegiline treated patients.  Selegiline-treated patients (< 
3 years) and non-selegiline treated patients transited at similar rates (Table 5.1).  The 
effect of selegiline on transition times from stage 1 to 2, 3 to 4 and 4 to 5 was not 
statistically significant.  The analyses could not be performed for levodopa for H&Y 
stage 2.5 and above in view of the small number of patients who were not treated with 
levodopa.  In all other H&Y transitions analysed, there was no significant association 
between each H&Y stage transition time and the use of levodopa, dopamine agonist, 
anti-cholinergics or amantadine.  
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Table 7.1 Cox regression analysis: hazard ratio for variables associated with progression in PD 
 
Transition from H&Y 
stage 2 to 2.5 
Transition from H&Y 















Gender       
Male (ref) 64.7%   58.2%   
Female 35.3% 1.04(0.64-1.69)  41.8% 1.14(0.72-1.81)  
Ethnicity       
Chinese (ref) 87.2%   90.5%   
Non-Chinese 12.8% 0.41(0.15-1.12)* 0.31 (0.07-1.33) 9.5% 1.20(0.55-2.61)  
†Age at diagnosis       
1st quartile (ref) <59   <60   
2
nd
 quartile 59-<66 1.19(0.54-2.61) 1.45(0.52-4.01) 60-<69 0.91(0.47-1.75)  
3rd quartile 66-<72 2.60(1.30-5.20)** 3.47(1.34-8.98)* 69-<80 1.39(0.74-2.62)  
4th quartile >72 4.50(2.30-8.77)*** 7.74(2.60-23.01)*** >80 1.07(0.57-1.20)  
†
Duration       
1st quartile (ref) 0   <1 mo   
2nd quartile 1 mo 1.59(0.66-3.81) 1.64(0.61-4.41) 2-<18 mo 1.31(0.65-2.66)  
3
rd
 quartile 2-<7 mo 2.93(1.26-6.85)* 2.91(1.14-7.42)* 18 mo-<4 yr 1.72(0.88-3.36)  
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4
th
 quartile >7 mo 2.54(1.10-5.84)* 3.51(1.32-9.33)* >4 yr 1.69(0.89-3.21)  
†UPDRS       
1st quartile (ref) <14   <19   
2nd quartile 14-<18 2.79(1.16-6.70)* 4.31(1.57-11.87)** 19-<24 0.78(0.34-1.76)  
3rd quartile 18-<25 2.37(0.96-5.88)* 2.47(0.90-6.76) 24-<31 1.20(0.58-2.50)  
4
th
 quartile >25 5.64(2.43-13.09)*** 5.16(1.98-13.48)** >31 1.18(0.59-2.40)  
Levodopa       
No (ref) 12.8%   2.1% 
‡Nil  
Yes 87.2% 1.39(0.44-4.43)  97.2%   
Dopamine Agonist       
No (ref) 61.8%   34.9%   
Yes 38.2% 1.62(1.01-2.60)* 1.62(0.76-3.45) 65.1% 1.50(0.95-2.38)  
Selegiline       
No (ref) 61.5%   73.0%   
Yes (<3 yrs) 24.8% 0.57(0.32-1.01) 1.27(0.60-2.65) 11.6% 0.92(0.47-1.81) 0.77(0.39-1.55) 
Yes (>=3 yrs) 13.7% 0.16(0.07-0.36)*** 0.24(0.09-0.63)** 15.3% 0.44 (0.23-0.85)* 0.35(0.18-0.69)** 
COMT Inhibitors       
No (ref) 94.9%   84.7%   
Yes 5.1% 1.96(1.03-3.72)* 2.89(1.25-6.66)* 15.3% 1.76(1.06-2.93)* 2.3(1.35-3.92)** 
HR: hazard ratio 
95% CI: 95% confidence interval 
Ref: reference group 
*P <0.05 
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**P<0.01 
***P<0.001 
Mo: months, Yr: years 
†Individual categories of age at diagnosis measured in years, duration at study entry and UPDRS vary for different H&Y stage transition 
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In multivariate Cox regression analysis, after adjusting for potential 
confounders, patients who were of younger age, shorter PD duration, lower UPDRS 
motor scores, on selegiline treatment (≥ 3 years) and not on COMT inhibitors were 
associated with longer transition times from stage 2 to 2.5.  Patients who were treated 
with selegiline for more than 3 years and not on COMT inhibitors experienced longer 
transition times from stage 2.5 to 3 (Table 7.1).  The results of multivariate analyses 
with selegiline duration for transitions from stage 2 to 2.5 and 2.5 to 3 are presented in 
Figure 7.1.  Mean transition time from stage 2 to 2.5 was 63 vs. 43 months (p=0.004) 
and from stage 2.5 to 3 was 42 vs. 24 months (p=0.002) for selegiline-treated patients 
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Figure 7.1 Transition from stage 2 to 2.5 and 2.5 to 3 categorized by duration of selegiline use 
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DISCUSSION 
This study analyzed transition times from one H&Y stage to the next and 
evaluated the association between selegiline use and progression of PD in a “real-life”, 
naturalistic setting that accounted for baseline demographic and clinical variables in a 
survival analysis.  The results revealed that patients treated for more than 3 years with 
selegiline experienced significantly longer transition times from stage 2 to 2.5 and 2.5 
to 3 compared to patients not treated with selegiline.  The findings that patients of 
younger age, shorter PD duration, and lower UPDRS motor scores were associated 
with longer transition times from stage 2 to 2.5 are consistent with what we have 
reported before.160   
 
The beneficial effects of selegiline were found only for H&Y transitions 2 to 
2.5 and 2.5 to 3.  These effects were not significant for transitions between H&Y 
stages 1 to 2, 3 to 4 and 4 to 5.  One possible explanation for the lack of association 
between selegiline and H&Y stage transition from stage 1 to 2 could be the small 
sample size with only 5 out of 40 selegiline-treated patients on the drug for more than 
3 years.  The reason for the lack of association between selegiline treatment and H&Y 
transitions in advanced stages could be the result of selegiline’s ability to only 
influence the compensatory response mechanisms in early PD.  In advanced PD, such 
compensatory mechanisms break down and new factors that accelerate the disease 
course come into play.   
 
Selegiline was found to be beneficial in early PD for patients treated for at 
least 3 years.  Our findings were consistent with those from an earlier study which 
showed a divergence of UPDRS scores only after 3 years of treatment between 
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patients on selegiline versus placebo.
40
  These results showed that it takes about 3 
years of selegiline treatment in a clinic setting before a significant association 
between selegiline use and a slower progression of early PD can be demonstrated.  
Such an observation suggests that selegiline may have disease modifying effects that 
cannot be explained by its mild symptomatic effects nor its effect in making more 
dopamine available in the nigrostriatal synapse.  This is because, if these latter effects 
were in play, then prolonged H&Y transition times should be observed in all 
selegiline-treated patients regardless of its treatment duration or H&Y stage.  Another 
possible explanation for this association could be the presence of a selection bias with 
selegiline preferentially being used to treat relatively stable patient who were at lower 
risk of disease progression and withheld from patients at higher risk of disease 
progression such as those with complications of orthostatic hypotension or 
hallucinations.  However, this bias is unlikely to account for the results as these were 
early PD patients with average disease duration of 0.8 to 3.1 years where such 
complications occur infrequently.  Furthermore, this bias, if present, would result in a 
similar association with the use of dopamine agonists and be more significant in 
advanced PD patients.  However, no association with H&Y transition times was found 
in these patient groups.   
 
When other PD medications were analysed in the multi-variate analysis, 
levodopa and dopamine agonists were not associated with H&Y transition times in 
early PD.  These findings are consistent with our current understanding that both these 
drugs do not modify the progression of PD.161 COMT inhibitors were found to be 
associated with a more than 2 fold increased risk of a more rapid H&Y transition in 
early PD.  As the current indication for the use of COMT inhibitors is to manage 
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motor complications, patients on COMT inhibitors likely represent the subset of 
patients with a more rapidly progressing disease thus accounting for this increased 
risk.     
 
In conclusion, we found that levodopa or dopamine agonist use did not affect 
H&Y transition times.  Selegiline use for 3 years or more in early PD was associated 
with a slower progression of PD as evaluated by H&Y transition times.  These 
findings strengthen the evidence that MAO-B inhibitors, such as selegiline, modify 














Cost Utility Analyses of Selegiline in Parkinson’s Disease in 
a Multi-ethnic Asian Population 
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INTORDUTION 
Parkinson’s disease (PD) is a chronic neurodegenerative disorder which is 
characterized by motor disability as well as non-motor impairment including 
cognitive, emotional, sensorial and autonomic aspects. Besides its substantial impact 
on patients’ functional status and well being, PD also imposed a significant economic 
burden
126, 129, 136
 and impaired Health Related Quality of Life (HRQoL) of PD 
patients.49, 53 
 
Levodopa remains the most commonly used drug in PD. However, prolonged 
use of levodopa eventually leads to long-term motor complications which 
substantially reduces patients’ HRQoL.
35
 Medications from a number of drug classes 
are increasingly considered as initial therapy for delaying levodopa-related motor 
complications or are often given adjunctively to mitigate motor fluctuations during 
levodopa therapy. Selegiline, a monoamine oxidase type B (MAO-B) inhibitor, was 
first introduced in 1990s in order to delay or treat levodopa related motor 
complications. The dopamine agonists and catechol-O-methyl transferase (COMT) 
inhibitors subsequently emerged. Selegiline is often considered as less efficacious 
than dopamine agonists or COMT inhibitors due to its weak symptomatic effect and 
limited reduction on “off” time.36, 37 Yet, in recent years, there has been a shift in the 
role of MAO-B inhibitors (selegiline and its second generation i.e. rasagiline) in PD 
treatment due to their potential disease modifying effect. The ADAGIO study 
concluded that early treatment with rasagiline at a dose of 1mg per day provided 
benefits that were consistent with a possible disease-modifying effect.38 
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Rasagiline is however not widely available globally.  Its use has so far been 
primarily restricted to North America and Europe with many other regions of the 
world depending on selegiline for MAO-B inhibition. As reported in a few clinical 
trials, the use of selegiline in early PD may slow progression and improve long-term 
outcome.39-41 Our recent study also confirmed that selegiline slows the progression in 
early PD as evaluated by Hoehn and Yahr stage transition times (Chapter 7).
162
 As 
selegiline delays the onset of disability in early PD, it may be expected to have a 
favorable impact on HRQoL of PD patients, an important outcome indicator for 
evaluating the effectiveness of health care. Moreover, selegiline is cheaper than most 
other PD drugs. Given that it is less efficacious in symptom control but may be able to 
modify the disease progression, it warrants a pharmacoeconomics analysis even 
though this is rarely performed because most new drugs are expensive. We postulated 
that the lower efficacy of selegiline with regards to its weak symptomatic effect and 
limited reduction of “off” time will be offset by its disease modifying effect and that 
the overall benefits of selegiline will be adequately captured by HRQoL assessment. 
Hence, we aimed to perform a cost-utility analysis of selegiline in early PD among 
multi-ethnic Asian patients in Singapore.  
 
To the best of our knowledge, formal pharmacoeconomic analyses involving 
selegiline has not yet been performed in any population. The information obtained 
from this study would assist the decision makers in setting priorities for resource 
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This study is a secondary analysis of a larger dataset. The dataset was 
previously used to report disease progression based on H&Y staging (Chapter 4)156, 
the annual economic burden of PD (Chapter 5)154 and the impact of selegiline on 
disease progression in PD (Chapter 7).162 For a detailed description of the study 
design, please refer to Chapter 5.154 Information that is relevant to this study will be 
summarized here. A sample of consecutive patients seen at the PD and Movement 
Disorders Centre of the National Neuroscience Institute (NNI), a secondary and 
tertiary referral centre for both public and private sectors in Singapore, between April 
and December 2008 were recruited. Patients meeting the National Institute of 
Neurological Disorders and Stroke criteria for the diagnosis of Parkinson’s disease 
with follow-up of at least a year were included. All patients were evaluated in the on 
state. Patients who could not understand English or Chinese were excluded because 
the 8-item Parkinson’s Disease Questionnaire (PDQ-8)4 questionnaire for assessing 
Parkinson-specific HRQoL was available in these languages only. Further information 
on the PDQ-8 was not provided in this study as data from the PDQ-8 were not 
incorporated in this analysis. Patients (or proxies) were interviewed by a single 
interviewer using their preferred choice of either English or Chinese standardized 
questionnaires including a financial burden questionnaire, two HRQoL questionnaires 
(PDQ-8 and EuroQoL (EQ-5D)3). 
 
Model structure 
We employed the Markov model to perform a cost utility analysis of treatment 
incorporating selegiline versus treatment without selegiline in early PD. The Markov 
model comprised of three mutually exclusive health states defined by modified Hohn 
and Yahr stages and was constructed using TreeAge Pro 2009 (Williamstown, MA. 
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USA) (Figure 8.1). A cohort of 1000 patients started the cycle in H&Y stage 1. The 
cycle length was defined as one year because the transition from one H&Y stage to 
the next or death rarely occurs more than once a year. The probability of moving to 
other states or remaining in the same states was defined by a transition probability 
matrix (see next section). Each state except dead is associated with specific cost and 
benefit. As PD is a progressive neurodegenerative disease, patients in our study were 
assumed to progress from one Markov state to the next state or dead over the course 
of the disease without skipping or regressing (i.e. patients cannot experience 
improvement in health). The evaluation took a societal perspective, thus incorporating 
direct medical, direct non-medical and indirect cost. The model followed up the 
patients until they died or when they on average reached the age of 85 years which is 
the average life expectancy of Singapore’s resident population at age 65 years.155 
Treatments with an incremental cost-effectiveness ratio of less than SGD14493 (USD 
PPP 12940) per quality adjusted life years (QALYs) were considered as cost-effective 
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The cost associated with each Markov health state was previously reported 
(Chapter 5).154 Cost was estimated using a bottom-up approach using a combination 
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of hospital administrative databases and patient interviews using a financial burden 
questionnaire. Direct medical cost was computed using hospital databases 
(hospitalization, outpatient visit, pharmacotherapy, ancillary treatment and emergency 
services) and patient interviews (hospitalization in other hospitals, clinic visits to GPs 
and other hospitals, nursing home care and day care center). Direct non-medical cost 
such as home care was captured using patient interviews where home care was 
defined as care provided by domestic helpers. Indirect cost which comprises 
productivity loss (due to sick leave, reduced salary, early retirement, and presenteeism 
at work) and informal care was estimated using the human capital approach, with an 
exception in the estimate of productivity losses by home makers, which was estimated 
using the opportunity cost approach. Presenteeism at work, measured using a 0% to 
100% visual analogue scale (VAS), was defined as potential productivity loss in both 
work and housekeeping services over the past 12 months. Informal care refers to 
productivity losses incurred when family members took short-term leave or gave up 
full-time employment to take care of the patients. All cost was valued as 
1USD=1.12SGD based on Purchasing Power Parity (PPP) published in the Economist 
in 2009.145 
 
State-specific Utility  
The utility of PD patients were evaluated by quality adjusted life years 
(QALYs). In Chapter 5,
154
 patients were administered the EQ-5D self-reported 
instrument to assess QALYs. EQ-5D is one of the most popular preference-based 
instruments which is made up of a self-classifier and a visual analogue scale (VAS). 
The self-classifier comprises five dimensions including mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression, with each dimension described as 
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having no problems, moderate problems, or severe problems. A total of 243 possible 
health states can be defined and each is associated with a utility score (range: -0.594 
to 1) derived using the Time Trade off technique. The EQ-5D has previously 
demonstrated good measurement properties in several local studies142, 143 was used to 
compute QALYs in SPSS 17.0 for Windows (SPSS Inc, Chicago, IL) in our study. 
 
Transition Probability  
The times taken to transit from one H&Y stage to the next was calculated 
using Cox Proportional-Hazards Regression model to adjust for potential confounders 
i.e. gender, ethnicity, disease duration and severity and was previously reported for 
patients who received and who did not receive selegiline, respectively (Chapter 4).
156
 
The reported transition times was converted to transition probability using the 
following formula: P= 1-exp(-rt) where P is the transition probability, r is the 
reciprocal of time taken to progress  through various H&Y stages and t is the cycle 
length.157  Due to limited data on the impact of selegiline on mortality, mortality rate 
was assumed to be the same for both selegiline and non-selegiline treated patients. 
Probabilistic sensitivity analysis (PSA) was performed on mortality estimate to 
evaluate the robustness of this assumption.  
 
Sensitivity analysis 
One-way sensitivity analyses and tornado diagram were used to estimate the 
impact of extreme values (minimum to maximum) of each model parameter on the 
model results. PSA with 1000 sampling was performed on the model parameters 
including total cost, utility and transition probability to assess the impact of changing 
those parameters individually and simultaneously. In PSA, the cost parameters 
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assumed gamma distributions; while positive utility and transition probability 
assumed independent beta distributions. For negative utility, a transformation of 




Both cost and utility were discounted at 5% as suggested by submission 




One hundred and ninety one patients with complete drug information were 
eventually included in our analysis. The characteristics of patients who were treated 
with or without selegiline are summarized in Table 8.1. As shown by UPDRS motor 
scores, selegiline treated patients had a similar disease severity with non-selegiline 
treated patients. Total cost and utility score at per H&Y stage between selegiline and 
non-selegiline treated patients which were used to perform cost utility analysis are 
summarized in Table 8.2.  
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Table 8.1 Characteristics of patients who did and did not receive selegiline 
 Selegiline treated patients Non-selegiline treated patients 
H&Y stage 1 2 2.5 3 4 5 1 2 2.5 3 4 5 
Number of patients 6 34 7 10 8 8 8 39 23 21 20 7 
Male 50.0% 79.4% 71.4% 60.0% 37.5% 37.5% 37.5% 48.7% 43.5% 47.6% 25.0% 28.6% 
Chinese 83.3% 85.3% 100% 90.0% 100.0% 75.0% 87.5% 97.4% 91.3% 95.2% 85.0% 100.0% 
Age 57.9 yr 64.0 yr 67.1 yr 67.4 yr 71.8 yr 75.1 yr 65.2 yr 66.6 yr 69.7 yr 68.1 yr 73.5 yr 77.6 yr 
Duration 3.0 yr 4.9 yr 5.8 yr 10.1 yr 10.1 yr 10.2 yr 4.0 yr 5.6 yr 4.0 yr 6.1 yr 8.0 yr 7.2 yr 
UPDRS motor scores 10.3 17.5 29.6 29.1 40.5 54.9 9.8 18.2 24.9 29.4 42.0 56.4 
H&Y stage: Hoehn & Yahr stage 
UPDRS: Unified Parkinson’s Disease Rating Scale 
Yr: years
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Table 8.2 Model Parameters by H&Y stages* 





Parameter Mean (SD) Mean (SD) Distribution** 
H&Y Stage 1    
Total cost 4765 (4933) 7059 (14072) Gamma 
Positive utility 
scores 
0.838 (0.132) 0.774 (0.157) Beta 
H&Y Stage 2    
    
Total cost 11890 (16912) 12930 (30650) Gamma 
Positive utility 
scores 
0.767 (0.235) 0.730 (0.210) Beta 
H&Y Stage 2.5    
    
Total cost 10398 (23042) 17679 (54861) Gamma 
Positive utility 
scores 
0.519 (0.220) 0.655 (0.216) Beta 
H&Y Stage 3    
    
Total cost 5952 (4003) 11272 (10144) Gamma 
Positive utility 
scores 
0.530 (0.348) 0.491 (0.261) Beta 
H&Y Stage 4    
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Total cost 9668 (4671) 7677 (11049) Gamma 
Positive utility 
scores 
0.392 (0.256) 0.365 (0.243) Beta 
H&Y Stage 5    
    
Total cost 10680 (6880) 13452 (7067) Gamma 
Disutility score -0.053 (0.163) -0.146 (0.158) Gamma 
SD: standard deviation 
* Data were derived from our previous study on economic burden of PD in 
Singapore154 
**In PSA, the distribution assumed to parameters was derived from decision 
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Transition probability 
Transition probability imputed by the time to transition from one stage to the 
next or death in our previous study was shown in Table 8.3. Selegiline treated patients 
had slower progression from stage 1 to 2, 2 to 2.5, 2.5 to 3 and 4 to 5 than non-
selegiline treated patients; while, selegiline treated patients had faster progression 
from stage 3 to 4 than non-selegiline treated patients. The rate in slower progression 
from stage 4 to 5 is much smaller than early stage transitions between selegiline and 
non-selegiline treated patients.  
 
Cost utility analysis 
Over the life time follow-up, total cost attributable to selegiline treated 
patients was lower than that attributable to non-selegiline treated patients with a mean 
cost saving of SGD19026 (USD PPP 16988) (Table 8.4). The QALYs of selegiline 
treated patients were higher (indicating better HRQoL) than non-selegiline treated 
patients. The incremental cost utility ratio (ICUR) is –SGD59086 (USD PPP 52755) 
per additional QALY gained over life-time period of selegiline vs. non selegiline 
treated patients. Hence, treatment incorporating selegiline is a dominant 
pharmacotherapy in early PD compared to treatment without selegiline. 
 
Sensitivity analysis 
In one-way sensitivity analyses, treatment incorporating selegiline was not 
cost-effective compared to treatment not incorporating selegiline when the following 
model parameters were included in the analysis: cost at H&Y stage 2 and 2.5 in 
treatment incorporating selegiline arm, cost at H&Y stage 2 in treatment not 
incorporating selegiline arm as well as utility at H&Y stage 2 in treatment 
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incorporating selegiline arm (Table 8.5). According to the tornado diagram 
constructed based on the results of the one-way sensitivity analyses, the top three 
determinants on model results were cost at H&Y stage 2 and 2.5 and utility at H&Y 
stage 2 (Figure 8.2).  
 
However, the dominance of treatment incorporating selegiline over without 
selegiline was maintained throughout PSA (Table 8.6) involving total cost, transition 
probabilities and utility estimates. Hence, our base case analysis was robust.  
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Table 8.3 Transition probability from one H&Y stage to the next or death*  
Selegiline treated patients Non-selegiline treated patients Commencing 
H&Y stage Probability of entering H&Y stage Probability of entering H&Y stage 
  1 2 2.5 3 4 5 Death 1 2 2.5 3 4 5 Death 
1 0.607 0.393 Nil Nil Nil Nil 0.000 0.532 0.468 Nil Nil Nil Nil 0.000 
2 Nil 0.672 0.176 Nil Nil Nil 0.152 Nil 0.605 0.243 Nil Nil Nil 0.152 
2.5 Nil Nil 0.563 0.271 Nil Nil 0.167 Nil Nil 0.440 0.393 Nil Nil 0.167 
3 Nil Nil Nil 0.426 0.370 Nil 0.204 Nil Nil Nil 0.491 0.305 Nil 0.204 
4 Nil Nil Nil Nil 0.425 0.359 0.216 Nil Nil Nil Nil 0.403 0.381 0.216 
5 Nil Nil Nil Nil Nil 0.575 0.425 Nil Nil Nil Nil Nil 0.575 0.425 
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Table 8.4 Life time cost utility between selegiline and non-selegiline treated patients 
 Total cost QALYs ICUR($/QALY)  
Selegiline treated patients 57767 4.48 -59086 Dominant 
Non-selegiline treated patients 76793 4.17  Dominated 
QALYs: quality adjusted life years 
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Table 8.5 One-way sensitivity analysis 
  Selegiline treated patients Non-selegiline treated patients  
Model parameter  Total cost Utility Total cost Utility ICUR ($/QALY) 
Total cost for selegiline 
treated patients 
      
H&Y 1       
Min 675 50128 4.476 76793 4.157 Dominated* 
Max 14045 75098 4.476 76793 4.157 Dominated* 
H&Y 2       
Min 226 29044 4.476 76793 4.157 Dominated* 
Max 63475 184794 4.476 76793 4.157 338756** 
H&Y 2.5       
Min  335 48847 4.476 76793 4.157 Dominated* 
Max 62406 103865 4.476 76793 4.157 84915** 
H&Y 3       
Min 852 53145 4.476 76793 4.157 Dominated* 
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Max 13105 64249 4.476 76793 4.157 Dominated* 
H&Y 4       
Min 3998 55872 4.476 76793 4.157 Dominated* 
Max 16471 60039 4.476 76793 4.157 Dominated* 
H&Y 5       
Min 972 56178 4.476 76793 4.157 Dominated* 
Max 21357 59514 4.476 76793 4.157 Dominated
*
 
Total cost for non-selegiline 
treated patients 
      
H&Y 1       
Min 574 57767 4.476 66896 4.157 Dominated* 
Max 41672 57767 4.476 129614 4.157 Dominated
*
 
H&Y 2       
Min 486 57767 4.476 50296 4.157 23433** 
Max 178137 57767 4.476 428568 4.157 Dominated* 
H&Y 2.5       
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Min 332 57767 4.476 62057 4.157 Dominated* 
Max 266229 57767 4.476 287928 4.157 Dominated
*
 
H&Y 3       
Min 913 57767 4.476 60625 4.157 Dominated* 
Max 34159 57767 4.476 112514 4.157 Dominated* 
H&Y 4       
Min 1123 57767 4.476 74236 4.157 Dominated
*
 
Max 52747 57767 4.476 94372 4.157 Dominated* 
H&Y 5       
Min 4966 57767 4.476 74974 4.157 Dominated* 
Max 24068 57767 4.476 79068 4.157 Dominated* 
Utility for selegiline treated 
patients 
      
H&Y 1       
Min 0.73 57767 4.274 76793 4.157 Dominated* 
Max 1 57767 4.779 76793 4.157 Dominated* 
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H&Y 2       
Min -0.02 57767 2.538 76793 4.157 11751*** 
Max 1 57767 5.050 76793 4.157 Dominated* 
H&Y 2.5       
Min 0.08 57767 4.089 76793 4.157 282177† 
Max 1 57767 4.905 76793 4.157 Dominated* 
H&Y 3       
Min -0.18 57767 3.870 76793 4.157 66186
†
 
Max 1 57767 4.939 76793 4.157 Dominated* 
H&Y 4       
Min -0.11 57767 4.309 76793 4.157 Dominated* 
Max 0.64 57767 4.559 76793 4.157 Dominated
*
 
H&Y 5       
Min -0.18 57767 4.455 76793 4.157 Dominated* 
Max 0.15 57767 4.509 76793 4.157 Dominated* 
Utility for non-selegiline       
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treated patients 
H&Y 1       
Min 0.52 57767 4.476 76793 3.771 Dominated* 
Max 1 57767 4.476 76793 4.504 Dominated* 
H&Y 2       
Min 0.08 57767 4.476 76793 2.777 Dominated* 
Max 1 57767 4.476 76793 4.736 73078† 
H&Y 2.5       
Min -0.07 57767 4.476 76793 3.544 Dominated* 
Max 1 57767 4.476 76793 4.453 Dominated* 
H&Y 3       
Min 0 57767 4.476 76793 3.394 Dominated
*
 
Max 0.81 57767 4.476 76793 4.658 104432
†
 
H&Y 4       
Min -0.09 57767 4.476 76793 3.980 Dominated* 
Max 0.71 57767 4.476 76793 4.292 Dominated* 
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H&Y 5       
Min -0.356 57767 4.476 76793 4.112 Dominated
*
 
Max 0.08 57767 4.476 76793 4.206 Dominated* 
Transition probability for 
selegiline treated patients 
      
H&Y 1 to 2       
Min 0.193 59981 5.683 76793 4.157 Dominated
*
 
Max 0.997 55844 3.600 76793 4.157 37609
†
 
H&Y 2 to 2.5       
Min 0.151 58091 4.518 76793 4.157 Dominated* 
Max 0.699 55644 4.160 76793 4.157 Dominated* 
H&Y 2.5 to 3       
Min 0.230 57716 4.469 76793 4.157 Dominated* 
Max 0.815 58343 4.531 76793 4.157 Dominated* 
H&Y 3 to 4       
Min 0.259 52678 4.555 76793 4.157 Dominated* 
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Max 0.795 58108 4.157 76793 4.157 Dominated* 
H&Y 4 to 5       
Min 0.277 57990 4.503 76793 4.157 Dominated* 
Max 0.733 56744 4.352 76793 4.157 Dominated* 
Transition probability for 
non-selegiline treated patients 
      
H&Y 1 to 2       
Min 0.312 57767 4.476 78676 4.648 121186
†
 
Max 0.997 57767 4.476 74533 3.579 Dominated* 
H&Y 2 to 2.5       
Min 0.187 57767 4.476 75713 4.194 Dominated* 
Max 0.757 57767 4.476 815225 4.050 Dominated
*
 
H&Y 2.5 to 3       
Min 0.271 57767 4.476 76800 4.156 Dominated* 
Max 0.830 57767 4.476 77064 4.169 Dominated* 
H&Y 3 to 4       
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Min 0.239 57767 4.476 77883 4.236 Dominated
*
 
Max 0.777 57767 4.476 68972 3.594 Dominated* 
H&Y 4 to 5       
Min 0.259 57767 4.476 76778 4.210 Dominated* 
Max 0.765 57767 4.476 76839 3.991 Dominated* 
*Treatment incorporating selegiline dominated treatment not incorporating selegiline as a cost effective treatment option  
**
Compared to treatment not incorporating selegiline, treatment incorporating selegiline was not cost-effective as its ICUR was more than 
SGD14493 (GBP PPP 20000) 
***Compared to treatment incorporating selegiline, treatment not incorporating selegiline was cost-effective as its ICUR was less than 
SGD14493 (GBP PPP 20000) 
†Compared to treatment incorporating selegiline, treatment not incorporating selegiline was not cost-effective as its ICUR was more than 
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Table 8.6 Probabilistic sensitivity analysis  
 Selegiline treated patients Non-selegiline treated patients  
 Total cost Utility 
 
Total cost Utility ICUR 
($/QALY) 
Parameter (univariate) Range Range Range Range  
Total cost 3958-501735 4.463-4.463 2598-912204 4.138-4.138 -56258 
Transition probability 44437-77679 3.615-5.944 60388-92807 3.363-5.204 -55613 
Utility 56672-56672 1.525-5.918 75797-75709 2.070-5.793 -64197 
Parameter (multivariate)      
Total cost, 




1.971-6.977 3108-604055 1.450-6.132 -57702 
ICUR: incremental cost utility ratio 
QALYs: quality adjusted life years 
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Figure 8.2 Tornado diagram (willingness to pay=SGD 14493) 
 
CY2: cost at H&Y stage 2 in treatment incorporating selegiline arm 
CY25: cost at H&Y stage 2.5 in treatment incorporating selegiline arm 
UY2: utility at H&Y stage 2 in treatment incorporating selegiline arm 
P12: transition probability from H&Y stage 1 to 2 
CY1: cost at H&Y stage 1 in treatment incorporating selegiline arm 
UY3: utility at H&Y stage 3 in treatment incorporating selegiline arm 
UY25: utility at H&Y stage 2.5 in treatment incorporating selegiline arm 
CY3: cost at H&Y stage 3 in treatment incorporating selegiline arm 
UY1: utility at H&Y stage 1 in treatment incorporating selegiline arm 
P34: transition probability from H&Y stage 3 to 4 
CY4: cost at H&Y stage 4 in treatment incorporating selegiline arm 
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DISCUSSION 
Our study in a clinic based population showed that treatment incorporating 
selegiline in early PD patients was cost effective compared to treatment without 
selegiline over a life time period. Selegiline treated patients have a relatively slower 
progression, lower life time economic burden and higher life time utility score, which 
resulted in an ICUR of –SGD59086 (-USD PPP 52755) per additional QALY gained 
compared to non-selegiline treated patients.  
 
This study was the first to report on the cost-effectiveness of selegiline and 
lent further support to previous findings in clinical trials that selegiline may delay 
disease progression.
39-41
 The sensitivity analyses show that these results are robust to 
changes in the assumptions for calculation of costs, utility and transition probabilities. 
Deterministic analysis revealed that better estimates of cost at H&Y stage 2 and 2.5 
and utility at H&Y stage 2 were needed as the conclusions were sensitive to these 
estimates. Nevertheless, selegiline remained dominant in all PSA. PSA is generally 




A Cochrane review of two clinical trials165 involving selegiline with dopamine 
agonist (in both studies) and selegiline with levodopa (in one study) suggested that 
selegiline may be a useful option for the early treatment of PD. The review reported 
that selegiline was not associated with a significant increase or decrease in deaths 
compared with levodopa (odds ratio (OR) 0.96; 95% confidence interval (CI) 0.52 to 
1.76) or dopamine agonists (OR 1.30; 95% CI 0.69 to 2.45); that patients on selegiline 
experienced reduction in motor fluctuations compared with levodopa (OR 0.55; 95% 
CI 0.32 to 0.94) but not dopamine agonists (OR 1.15; 95% CI 0.65 to 2.05); and that 
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withdrawals due to adverse events were less common with selegiline than with 
dopamine agonists (OR 0.11; 95% CI 0.01 to 0.99). By incorporating both clinical 
and economic data, our study provided an additional dimension of information 
important to medical decision makers.   
 
Strength of this paper lies in the use of data from clinical sample from an 
actual clinical setting. Current guidelines for publishing economic evaluation 
encourage the use of data from clinical studies employing a "pragmatic" protocol over 
clinical trials as these are often more generalisable.159 The use of clinical data also 
allows us to take “real-world” medication adherence rates into account, thus 
addressing concerns that failure to incorporate such data would lead to the selection of 
suboptimal treatment strategies.166 In addition, we incorporated indirect cost and 
informal care which are often not included in economic evaluation because they are 
difficult to measure.167 Whetten-Goldstein et al.168 had reported that informal cost was 
the largest component of indirect cost. Furthermore, we estimated the cost 
effectiveness of selegiline in a large clinical based PD population who were medically 
treated by movement disorder specialists who adopted the treatment guidelines of the 
American Academy of Neurology.106 Hence, our findings would provide more useful 
information in clinical practice compared to studies that incorporated only clinical 
trials data.169 While economic simulation model such as the one that we had used in 
this study do not necessarily replicate the real world setting, it offers opportunities for 
examining the impact of varying assumptions related to both cost and outcome. The 
conclusions may also be easily updated and reviewed as new information become 
available.     
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Naturally, our study has some limitations. First of all, due to data availability, 
in the model we did not allow patients to skip or improve in disease stages and 
assumed all patients have the same mortality rate. However, as evaluated in PSA, the 
results on cost effectiveness were not sensitive to the changes of mortality rate. 
Second, the cost and utility score at base case were derived from a relatively small 
sample of PD population. Nevertheless, PSA showed that variations in the ICUR was 
not sensitive to changes in cost and utility estimates. Finally, we assumed medication 
adherence to be 100% and did not evaluate the impact of reduced medication 
adherence on ICUR as we did not have data with regards to the impact of medication 
non-adherence on disease progression.   
 
In conclusion, our study results support the use of treatment incorporating 
selegiline as a cost-effective pharmacotherapeutic option in early PD compared to 
treatment without selegiline in a societal perspective.  
 











A Recapitulation of Major Findings, Contributions, 
Limitations, and Future Studies 
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In the last chapter of this thesis, I would like to recapitulate major findings 
made in this thesis as a way to assess how adequately these studies have investigated 
HRQoL and pharmacoeconomic outcomes of PD in an Asian context. At the same 
time, the major contributions and limitations of this thesis would also be discussed. 
Following this, I would like to provide some recommendations on future studies 
which would further improve the holistic management of PD in Asia.  
 
Major findings 
This thesis may be broadly divided into two sections. In the first section of the 
study (Chapters 2 and 3), we investigated HRQoL related topics among Asian patients. 
In Chapter 2, we measured HRQoL among Asian patients with PD and found that 
both clinical and socio-demographics variables were associated with HRQoL in Asian 
patients with PD and these factors were associated with different aspects of patients’ 
HRQoL.  
 
In Chapter 3, in order to facilitate routine clinical use of HRQoL in both cross-
sectional and longitudinally setting as well as provide a reasonable interpretation of 
HRQoL scores, we investigated the psychometric properties of PDQ-8 and estimated 
the MID of PDQ-8 scores in a prospective longitudinal study. In this chapter, we 
elected to use three different criteria for assessing the psychometric properties and 
estimating the MID of PDQ-8. This practice, analogous to sensitivity analysis, 
provided us with multiple assessments and estimates, thus allowing us to evaluate the 
stability of our results. We found that the three criteria led to similar positive findings 
which suggest that the PDQ-8SI score was both reliable over time and sensitive to 
change in measuring HRQoL of Asian patients with PD in Singapore. According to 
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the three criteria, the MID values of PDQ-8SI in our study ranged from 5.8 to 7.4 
points.  
 
 In the second section of this thesis (Chapters 4 to 8), a series of studies was 
conducted to evaluate pharmacoeconomic outcomes in Asian patients with PD. In 
Chapter 4, we proposed a new approach to evaluate progression in PD by analyzing 
transition times between H&Y stages. This new approach would enable the design of 
medical decision making model for estimating the economic burden of PD in any 
countries (Chapters 5 and 6). Using this approach, estimates of the median duration at 
each H&Y stage were obtained. Our findings using this surrogate measure of disease 
progression was in line with previous studies that have used other measures of disease 
progression. For example, older age at diagnosis and longer duration of disease are 
associated with faster disease progression measured using H&Y stages.  
 
 In Chapter 5, it was reported that the annual total cost of PD from a societal 
perspective was SGD11345 (USD PPP 10129) per patient, with direct cost accounting 
for 38.5% and indirect cost accounting for 61.5%.  The main contributors to direct 
medical, direct non-medical and indirect cost were pharmacotherapy (50.4%), home 
care (76.1%) and productivity loss (97.9%), respectively. Higher education, younger 
age and longer duration of PD were associated with higher total cost. 
 
Besides estimates of cost in PD annually, it would be necessary to estimate 
life-time cost of PD in order to facilitate long-term economic evaluations of 
alternative interventions, given the growing availability of newer and more expensive 
pharmaceuticals and medical technology. Hence, in Chapter 6, we evaluated the life-
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time economic burden of PD by Markov modeling as well as proposed potential 
interventions to reduce those cost. The total life-time economic burden in a cohort of 
Singaporean PD patients was reported as SGD61206 (USD PPP 54648) per patient 
(direct medical, non-medical and indirect cost: 18.7%, 12.8% and 68.5%). 
Productivity loss amounting to SGD41437 (USD PPP 36997), the largest share of not 
only indirect but also total life-time economic burden of PD and amounted to. Hence, 
treatments and health care programmes i.e. physiotherapy, occupational therapies etc. 
with potential for returning patients to higher productivity are urgently needed. 
 
 In Chapter 7, we evaluated the effect of selegiline on PD progression in a 
clinical sample by evaluating the H&Y stage transition times. We found that being on 
selegiline treatment for 3 or more years as well as non-Chinese ethnicity, younger age, 
shorter duration, lower UPDRS and not taking COMT are associated with slower 
progression from stage 2 to 2.5. At the same time, being on selegiline treatment (> 3 
years) and not taking COMT remained associated with slower progression from stage 
2.5 to 3. For patients who were taking selegiline (> 3 years) or not taking selegiline, 
their mean transition times from stage 2 to 2.5 were 63 and 43 months, respectively; 
while, their mean transition time from stage 2.5 to 3 were 42 and 24 months, 
respectively.   
 
In Chapter 8, we combined HRQoL and economic data in the analysis. Using 
a life time Markov cohort model, treatment with selegiline in early PD patients was 
cost effective compared to treatment without selegiline from a societal perspective. 
Total life time cost attributable to selegiline treated patients was lower than that 
attributable to non-selegiline treated patients with a mean cost saving of SGD19026 
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(USD PPP 16988) and resulted in an ICUR of –SGD59086 (USD PPP 52755) per 
additional QALY gained compared to non-selegiline treated patients (a negative 
ICUR is favorable).  
 
Major contributions 
This thesis has contributed new information on HRQoL and 
pharmacoeconomic outcomes in Asian patients with PD which were previously 
unavailable. This would facilitate not only holistic management of PD in Asian 
patients but also rational healthcare decision making. The contributions of studies 
performed for this thesis are summarized as follows: 
 
First, to our best knowledge, our study was the first amongst Chinese patients 
with PD or in South-East Asia and one of the very few in Asia. We have identified 
factors associated with HRQoL as measure by PDQ-8. We have also identified 
differences in major HRQoL complains and factors associated with HRQoL between 
Western and Asian countries.  
 
Second, this is the first study that reported the reliability and responsiveness of 
PDQ-8. This provides a fundamental basis for the longitudinal use of PDQ-8 in both 
clinical research and practice. At the same time, the estimates of MID in PDQ-8 
would establish an important benchmark for interpreting HRQoL scores in both cross-
sectional comparisons of patient groups and longitudinal evaluation of treatment 
benefit. 
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Third, we developed a new approach to evaluate PD progression by analyzing 
the time taken for patients to transit from one H&Y stage to the next. The validity of 
this approach has been supported by the congruence between many findings from this 
new approach and other studies or clinical observations using different measures of 
disease progression. In contrast to the method of evaluating disease progression by 
prospectively following up patients from onset of the disease, this new approach 
would demand relatively less resource and time to be completed and would be easily 
applied in studies to evaluate the impact of alternative interventions on PD 
progression. 
 
Fourth, we have provided robust and detailed information regarding the 
economic burden of PD patients in Singapore by estimating both annual and life-time 
economic burden of PD from the societal perspective. A few important suggestions 
were proposed to local decision makers, healthcare professionals as well as patients in 
order to reduce the economic burden on the society as a whole: targeting treatments 
and health care programmes with potential for returning patients to higher 
productivity in view of the fact that productivity loss accounted for the largest share 
of both annual and total life time cost of PD, and adopting a flexible subsidy policy 
for PD patients based on disease severity.  
 
Fifth, we found that use of selegiline for 3 years or more in early PD resulted 
in a slower progression of PD from H&Y stage 2 to 2.5 and 2.5 to 3. This was the first 
study to evaluate the effect of selegiline on progression in a large clinical sample 
which represents ‘real-life’, naturalistic estimates as opposed to estimates derived 
from clinical trials that are conducted on select patient populations managed in a 
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controlled setting. These findings strengthen the evidence that MAO-B inhibitors, 
such as selegiline, modify disease progression in PD.     
 
Sixth, we provided evidence for decision makers as well as healthcare 
professionals that in a clinic-based population, treatment with selegiline was cost 
effective compared to treatment without selegiline. This finding may have impact on 
drug reimbursement decisions.   
 
Major limitations 
The limitations have been discussed in details in the individual chapters. The 
main limitation which could be applied throughout this thesis is the sampling issue.  
Due to the lack of knowledge in Malay or Tamil languages and limited financial 
resources, the study patients recruited were either Chinese-speaking or English-
speaking Singaporeans. The exclusion of non-English and non-Chinese speaking 
patients from our study has limited the generalizability of our findings to the general 
PD population in Singapore. However, this was a necessary compromise as the major 
HRQoL questionnaire, PDQ-8 used in this thesis was not available in Malay and 
Tamil and known discrepancies between proxy- and self-reported HRQoL 




The findings and limitations in the thesis have raised some new concerns and 
research questions that deserve to be investigated in the future.  
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A snap-shot study of exposure and outcome at a single point in time cannot 
determine the causal-effective relationship between variables studied. Thus, 
longitudinal studies need to be conducted to confirm the relationship between HRQoL 
and sociodemographic and clinical factors as the disease progresses. Additionally, the 
exclusion of non-English and non-Chinese speaking patients from our study has 
limited the generalizability to the general PD population in Singapore. We seek to 
develop the Malay and Tamil translations of the PDQ-8 questionnaire in the near 
future. 
 
We have also identified areas in which, the design of the Markov model used 
in our studies can be improved. For example, allowing patients to skip or improve in 
disease stages, incorporating the impact of reduced medication adherence; calculating 
the cost and utility score at base case from a relatively larger sample of PD population, 
etc.  
 
The future studies would provide more valuable information in PD 
management and improve the robustness of our findings.  
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Due to having Parkinson’s Disease, how often have you experienced the following problems during the last 
month? 
Please tick one box for each question. 
 
Due to having Parkinson’s disease, 
 
how often during the last month  
 
have you… 
   Never                Occasionally Sometimes  Often 
Always or  
cannot do at all 
○1  Had difficulty getting around  
        in public?                  
 
                            
○2  Had difficulty dressing     
       yourself?                   
 
                            
○3  Felt depressed? 
 
                        
○4  Had problems with your close 
       personal relationships?  
 
                            
○5  Had problems with your  
       concentration, e.g. when  
       reading or watching TV? 
 
                           
○6  Felt unable to communicate   
       with people properly? 
 
                           
○7  Had painful muscle cramps  
       or spasms?  
 
                           
○8  Felt embarrassed in public  
       due to having Parkinson’s  
       Disease? 
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B) Co-morbidities:  
1. Hypertension:  
(High blood pressure) 
1. Yes  
2. No                                                                        □                                      
2. Arthritis: 1. Yes 
2. No                                                                        □                                  
3. Diabetes 1. Yes 
2. No                                                                        □                                    
4. Congestive heart failure 1. Yes 
2. No                                                                        □                                  
5. Heart attack 
(Myocardial infarction) 
1. Yes 
2. No                                                                        □                                    
6. Stroke 1. Yes 
2. No                                                                        □          
7. Chronic Bronchitis 1. Yes 
A) Demographic Data  





3. NRIC/ HRN:  
4. Code:  
5. Date of diagnosis:  
5. Gender:            1. Male                   
2. Female                                                                                              □                                                                             
6. Race: 1. Chinese                 
2.  Malay  
3. Indian                    
4.  Others                                                                     
                                                                                                              □                                    
7. Home address:   
  170 
2. No                                                                        □                                     
8. COPD  
(Chronic obstructive pulmonary disease) 
1. Yes 
2. No                                                                        □                                     
9. Asthma 1. Yes 
2. No                                                                        □                                    
10. Depression 1. Yes 
2. No                                                                        □                                    
11. Migraine headaches 1. Yes 
2. No                                                                        □                                       
12. Ulcer 
(This could be stomach, duodenal or peptic 
ulcer) 
1. Yes 
2. No                                                                        □                                    
13. Liver 
(Any kind of liver condition) 
1. Yes 
2. No                                                                        □                                    
14. Kidney 
(Weak or failing kidneys-do not include 
kidney stones, bladder infections or 
incontinence) 
1. Yes 
2. No                                                                        □                                    
15. Cancer or malignancy of any kind 1. Yes 
2. No                                                                        □                                  
C) PD Clinical Data 
 
 
16. Total UPDRS ADL scores (part II)  
__________ 
Estimation date: 
______/_______/_______(DD/MM/YYYY)                               






______/_______/_______(DD/MM/YYYY)                        
  






______/_______/_______(DD/MM/YYYY)                               
 
19. Schwab & England ADL scale:  
__________% 
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20. Duration of dyskinesias. 
(What proportion of the waking day are 







1=1-25% of day 
2=26-50% of the day 
3=51-75% of the day 
4=76-100% of the day                                             
                                                                                 □    
Estimation date: 
______/_______/_______(DD/MM/YYYY)                               
21. Duration of wearing off.  
(What proportion of the waking day is the 
patient “off” on average?-UPDRS Q39) 
0=none 
1=1-25% of day 
2=26-50% of the day 
3=51-75% of the day 
4=76-100% of the day                                             
                                                                                  
□    
Estimation date: 
______/_______/_______(DD/MM/YYYY)                                    
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APPENDIX III Sample Instrument Extracted from EuroQol Questionnaire 
 
By placing a tick in one box in each group below, please indicate which statements 




I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
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APPENDIX IV Sample Instrument Extracted from Beck Depression Inventory 
(BDI) 
 
Name:        
NRIC:        
Date of Assessment:      
* Baseline/ 3 months/ 6 months/ 12 months/ Termination (*delete where applicable) 
 
Instructions: This questionnaire consists of 21 groups of statements. Please read each group 
of statements carefully, and then pick out the one statement in each group that best describes 
the way you have been feeling during the past two weeks, including today. Circle the 
number beside the statement you have picked. If several statements in the group seem to 
apply equally well, circle the highest number for that group. Be sure that you do not choose 
more than one statement for any group, including Item 16 (Changes in Sleeping Pattern) or 
Item 18 (Changes in Appetite). 
 
1.  Sadness 
0 I do not feel sad. 
1 I feel sad much of the time. 
2 I am sad all the time. 
3 I am so sad or unhappy that I can’t stand it. 
 
2.  Pessimism 
0 I am not discouraged about my future. 
1 I feel more discouraged about my future than 
I used to be. 
2 I do not expect things to work out for me. 
3 I feel my future is hopeless and will only get 
worse. 
 
3.  Past Failure 
0 I do not feel like a failure. 
1 I have failed more than I should have. 
2 As I look back, I see a lot of failures. 
3 I feel I am a total failure as a person. 
 
4.  Loss of Pleasure 
0 I get as much pleasure as I ever did from the 
things I enjoy. 
1 I don’t enjoy things as much as I used to. 
2 I get very little pleasure from the things I used 
to enjoy. 
5.  Guilty Feelings 
0 I don’t feel particularly guilty. 
1 I feel guilty over many things I have  
        done or should have done. 
2 I feel quite guilty most of the time. 
3 I feel guilty all of the time. 
 
6.  Punishment Feelings 
0 I don’t feel I am being punished. 
1 I feel I may be punished. 
2 I expect to be punished. 
3 I feel I am being punished. 
 
7.  Self- Dislike 
0 I feel the same about myself as ever. 
1 I have lost confidence as myself. 
2 I am disappointed in myself. 
3 I dislike myself. 
 
8.  Self-Criticalness 
0 I don’t criticize or blame myself more  
         than usual. 
1 I am more critical of myself than I used to be.
2 I criticize myself for all of my faults. 
3 I blame myself for everything bad that  
         happens. 
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3 I can’t get any pleasure from the things I used 
to enjoy. 
 
9.  Suicidal Thoughts or Wishes 
0 I don’t have any thoughts of killing myself. 
1 I have thoughts of killing myself, but I would 
not carry them out. 
2 I would like to kill myself. 
3 I would kill myself if I had the chance. 
 
10. Crying 
0 I don’t cry anymore than I used to. 
1 I cry more than I used to. 
2 I cry over every little thing. 
3 I feel like crying, but I can’t. 
 
11. Agitation 
0 I am no more restless or wound up than usual. 
1 I feel more restless or wound up than usual. 
2 I am so restless or agitated that it’s hard to 
stay still. 
3 I am so restless or agitated that I have to keep 
moving or doing something. 
 
12. Loss of Interest 
0 I have not lost interest in other people or 
activities. 
1 I am less interested in other people or things 
than before. 
2 I have lost most of my interest in other people 
or things. 
3 It’s hard to get interested in anything. 
 
13. Indecisiveness 
0 I make decisions about as well as ever. 
1 I find it more difficult to make decisions than 
usual. 
2 I have much greater difficulty in making 
decisions than I used to. 
3 I have trouble making any decisions. 
 
14. Worthlessness 




15. Loss of Energy 
0 I have as much energy as ever. 
1 I have less energy than I used to have. 
2 I don’t have enough energy to do very  
         much. 
3 I don’t have enough energy to do  
         anything. 
 
16. Changes in Sleeping Pattern 
0 I have not experienced any change in  
         my sleeping pattern. 
1a    I sleep somewhat more than usual. 
1b    I sleep somewhat less than usual. 
2a    I sleep a lot more than usual. 
2b    I sleep a lot less than usual. 
3a    I sleep most of the day. 
3b    I wake up 1-2 hours early and can’t get  
               back to sleep.                                                                                           
 
17. Irritability 
0 I am no more irritable than usual. 
1 I am more irritable than usual. 
2 I am much more irritable than usual. 
3 I am irritable all the time. 
 
18. Changes in Appetite 
0 I have not experienced any change in  
         my appetite. 
1a    My appetite is somewhat less than usual. 
1b    My appetite is somewhat greater than  
        usual. 
2a    My appetite is much less than before. 
2b    My appetite is much greater than usual. 
3a    I have no appetite at all. 
3b    I crave food al the time. 
 
19. Concentration Difficulty 
0 I can concentrate as well as ever. 
1 I can’t concentrate as well as usual. 
2 It’s hard to keep my mind on anything  
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1 I don’t consider myself as worthwhile and 
useful as I used to. 
2 I feel more worthless as compared to other 
people. 
3 I feel utterly worthless. 
20. Tiredness or Fatigue 
0 I am no more tired or fatigued than usual. 
1 I get more tired or fatigued more easily than 
usual. 
2 I am too tired or fatigued to do a lot of the 
things I used to do. 
3 I am too tired or fatigued to do most of the 
things I used to do. 
 
         for very long. 




21. Loss of Interest in Sex 
0 I have not noticed any recent change in  
         my interest in sex. 
1 I am less interested in sex than I used to be.
2 I am much less interested in sex now. 
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APPENDIX V Sample Instrument Extracted from Financial Burden 
Questionnaire 
 
1. Socio-demographic factors : 
 
1.1 Name: ____________________     
 
1.2 Code: ____________________     
 
1.3 Year of birth: □□□□  
 
1.4 Gender:  
1. Male 
2. Female                                                        
□ 
 




4. Others (please specify :__________)                                   
□ 
 
1.6 Current marital status:  
1. Married 
2. Single 
3. Divorced or separated  
4. Widowed                                                         
□ 
 
1.7 The highest level of education attained (patients could either state the 
certificate or the years of education they attained according to their preference):  
1. No formal education 
2. Incomplete Primary (did not obtain PSLE) 
3. PLSE (obtained certificate) 
4. Incomplete Secondary (did not get GCE “O” level) 
5. GCE “N” or “O” level 
6. ITE 
7. Polytechnic diploma 
8. University degree   
9. 0 year’ education 
10. 1-6 years’ education    
11. 7-12 years’ education 
12. >12 years’ education                                              
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□ 
 
1.8 Housing type:  
1. HDB 1-2 room flat 
2. HDB 3-4 flat 
3. HDB 5 room or executive flat 
4. Private condominium 
5. Landed property                                               
□ 
 
1.9 Household size (number of family members and maid living with patient): 
________persons   
 
2. Clinical visits and hospitalization due to your Parkinson’s disease 
(PD) or PD related problems in the past 12 months: 
 
2.1 Did you have clinical visits at TTSH for your PD or PD related problems 
including anxiety, depression, hallucination, dementia, urine problems, 
constipation and sleep problems et al. in the past 12 months?                                     
2.1.1  
1. Yes, if yes, please specify total numbers of visits: ________ 
2. No, if no, please proceed to question 2.2                                                      
□ 
2.1.2 How did you go to TTSH? (Patients could choose more than one option based 
on their own conditions) 
1. By bus or MRT, if yes, please specify total number uses: ________ 
2. By taxi or own car, if yes, please specify total number uses: ________ 
3. By walk  
□ 
 
2.2 Did you have clinical visits to GPs for your PD or PD related problems in the 
past 12 months?                                                    
2.2.1 
1. Yes, if yes, please specify the name or address of each clinic, total numbers of 
visits to each clinic followed by cost per visit (S$): 
______________________________ 
_____________________________________________________________________  
2. No, if no, please proceed to question 2.3                                                      
□ 
2.2.2 How did you go to the clinics? (Patients could choose more than one option 
based on their own conditions) 
1. By bus or MRT, if yes, please specify total number uses: ________ 
2. By taxi or own car, if yes, please specify total number uses: ________      
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3. By walking                                                            
□ 
 
2.3 Did you have clinical visits in other hospitals for your PD or PD related 
problems in the past 12 months?                                                    
2.3.1   
1. Yes, if yes, please specify the name or address of each hospital, total numbers of 
visits to each hospital followed by cost per visit (S$): _____________________ 
_____________________________________________________________________ 
2. No, if no, please proceed to question 2.4                                                          
□ 
2.3.2 How did you go to the hospitals? (Patients could choose more than one option 
based on their own conditions) 
1. By bus or MRT, if yes, please specify total number uses: ________ 
2. By taxi or own car, if yes, please specify total number uses: ________      
3. By walking                                                            
□ 
 
2.4 Did you have hospitalization at TTSH for your PD or PD related problems in 
the past 12 months:                                                    
2.4.1 
1. Yes, if yes, please specify total numbers of hospitalization and starting date of each 
hospitalization (DD/MM/YYYY): ________________________________________ 
2. No, if no, please proceed to question 2.5                                                           
□ 
2.4.2 How did you go to TTSH? (Patients could choose more than one option based 
on their own conditions) 
1. By bus or MRT, if yes, please specify total number uses: ________ 
2. By taxi or own car, if yes, please specify total number uses: ________      
3. By walking                                                            
□ 
 
2.5 Did you have hospitalization at other hospitals for your PD or PD related 
problems in the past 12 months?                                                    
2.5.1 
1. Yes, if yes, please specify the name or address of each hospital, the hospitalization 
periods from (DD/MM/YYYY) to (DD/MM/YYYY), total numbers of hospitalization 
of each hospital followed by cost per hospitalization (S$):_________________ 
_____________________________________________________________________
____________________________________________________________________ 
2. No, if no, please proceed to question 3.1                                                         
□ 
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2.5.2 How did you go to the hospitals? (Patients could choose more than one option 
based on their own conditions) 
1. By bus or MRT, if yes, please specify total number uses: ________ 
2. By taxi or own car, if yes, please specify total number uses: ________      
3. By walking                                                            
□ 
 
3. Complementary treatment due to your PD or PD related problems 
in the past 12 months:  
 
3.1 Did you take any traditional medicine because of your PD or PD related 
problems in the past 12 months:                                            
1. Yes, if yes, please specify the name of the medicine, total times of taking the 
medicine followed by the unit cost (S$): ___________________________________ 
_________________________________________________________________ 
2. No                                                           
□ 
 
3.2 Did you take any health supplements such as vitamins because of your PD or 
PD related problems in the past 12 months:                                                  
1. Yes, if yes, please specify the name of the health supplements, total times of taking 
the health supplements followed by the unit cost (S$): _____________________  
___________________________________________________________________ 




3.3 Did you practice any therapeutic exercise such as QiGong, Taichi, Yoga etc 
because of your PD or PD related problems in the past 12 months:                                                  
3.3.1 
1. Yes, if yes, please specify the name of each exercise, total number of visits, cost 
per visit (S$) followed by the address of the place you practiced exercise: 
_____________________________________________________________________
_____________________________________________________________________ 
2. No, if no, please proceed to question 3.4                                               
□ 
3.3.2 How did you go to the exercise place? (Patients could choose more than one 
option based on their own conditions) 
1. By bus or MRT, if yes, please specify total number uses: ________ 
2. By taxi or own car, if yes, please specify total number uses: ________      
3. By walking                                                             
□ 
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3.4 Did you take any massage therapy such as foot massage etc because of your 
PD or PD related problems in the past 12 months: 
3.4.1 
1. Yes, if yes, please specify total number of visits, cost per visit (S$) followed by the 
address of the place you took massage therapy: ______________________________ 
___________________________________________________________________ 
2. No, if no, please proceed to question 3.5    
□ 
3.4.2 How did you go to the massage place? (Patients could choose more than one 
option based on their own conditions) 
1. By bus or MRT, if yes, please specify total number uses: ________ 
2. By taxi or own car, if yes, please specify total number uses: ________      
3. By walking                                                            
□ 
 
3.5 Did you take any acupuncture therapy because of your PD or PD related 
problems in the past 12 months:  
3.5.1 
1. Yes, if yes, please specify total number of visits, cost per visit (S$) followed by the 
address of the place you took acupuncture therapy: __________________________ 
___________________________________________________________________ 
2. No, if no, please proceed to question 3.6    
□ 
3.5.2 How did you go to the acupuncture place? (Patients could choose more than one 
option based on their own conditions) 
1. By bus or MRT, if yes, please specify total number uses: ________ 
2. By taxi or own car, if yes, please specify total number uses: ________      
3. By walking                                                            
□ 
 
3.6 Did you take any aromatherapy because of your PD or PD related problems 
in the past 12 months: 
3.6.1 
1. Yes, if yes, please specify total number of visits, cost per visit (S$) followed by the 
address of the place you took aromatherapy: _____________________________ 
___________________________________________________________________ 
2. No, please proceed to question 3.7                                
□ 
3.6.2 How did you go to aromatherapy place? (Patients could choose more than one 
option based on their own conditions) 
1. By bus or MRT, if yes, please specify total number uses: ________ 
2. By taxi or own car, if yes, please specify total number uses: ________      
3. By walking                                                            
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□ 
 
3.7 Did you take any other complementary treatments because of your PD or PD 
related problems in the past 12 months: 
3.7.1 
1. Yes, if yes, please specify the name of the treatment, total number of visits, cost per 
visit (S$) followed by the address of the place you took treatment: 
_____________________________________________________________________ 
___________________________________________________________________ 
2. No, if no, please proceed to question 4.1                                                         
□ 
3.7.2 How did you go to the treatment place? (Patients could choose more than one 
option based on their own conditions) 
1. By bus or MRT, if yes, please specify total number uses: ________ 
2. By taxi or own car, if yes, please specify total number uses: ________      
3. By walking                                                            
□ 
 
4. Any following treatment due to your PD or PD related problems in 
the past 12 months? 
 
4.1 Did you have any visit to physiotherapist/ exercise classes because of your PD 
or PD related problems?                                                
4.1.1 
1. Yes, if yes, please specify total number of visits, cost per visit (S$) followed by the 
address of the place you took therapy: ___________________________________ 
___________________________________________________________________ 
2. No, if no, please proceed to question 4.2                                                          
□ 
4.1.2 How did you go to visit the physiotherapist? (Patients could choose more than 
one option based on their own conditions) 
1. By bus or MRT, if yes, please specify total number uses: ________ 
2. By taxi or own car, if yes, please specify total number uses: ________      
3. By walking                                                            
□ 
 
4.2 Did you have any visit to speech therapist because of your PD or PD related 
problems in the past 12 months? 
4.2.1 
1. Yes, if yes, please specify total number of visits, cost per visit (S$) followed by the 
address of the place you took therapy: ___________________________________ 
___________________________________________________________________ 
2. No, if no, please proceed to question 4.3                                                       
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□ 
4.2.2 How did you go to visit the speech therapist? (Patients could choose more than 
one option based on their own conditions) 
1. By bus or MRT, if yes, please specify total number uses: ________ 
2. By taxi or own car, if yes, please specify total number uses: ________      
3. By walking                                                            
□ 
 
4.3 Did you have any visit to occupational therapist because of your PD or PD 
related problems in the past 12 months? 
4.3.1 
1. Yes, if yes, please specify total number of visits, cost per visit (S$) followed by the 
address of the place you took therapy: ___________________________________ 
___________________________________________________________________ 
2. No, if no, please proceed to question 4.4                                                        
□ 
4.3.2 How did you go to visit the occupational therapist? (Patients could choose more 
than one option based on their own conditions) 
1. By bus or MRT, if yes, please specify total number uses: ________ 
2. By taxi or own car, if yes, please specify total number uses: ________      
3. By walking                                                            
□ 
           
4.4 Did you have any visit to others because of your PD or PD related problems 
in the past 12 months? 
4.4.1 
1. Yes, if yes, please specify the name of the therapy, total number of visits, cost per 
visit (S$) followed by the address of the place you took therapy: 
_____________________________________________________________________
___________________________________________________________________ 
2. No, if no, please proceed to question 5                                                    
□ 
4.4.2 How did you go to visit the therapist? (Patients could choose more than one 
option based on their own conditions) 
1. By bus or MRT, if yes, please specify total number uses: ________ 
2. By taxi or own car, if yes, please specify total number uses: ________      
3. By walking                                                            
□ 
 
5. Did you use A &E due to your PD or PD related problems in the 
past 12 months? 
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1. Yes, if yes, please specify total numbers of using A & E and cost per time (S$): 
_____________________________________________________________________ 
2. No                                                          
□ 
 
6. Did you need anyone to take care of you due to your PD or PD 
related problems in the past 12 months? (Patients could choose more than 





4. Maid, if yes, please specify the cost of maid per month including levy (S$) and 
period of providing the care from (DD/MM/YYYY) to (DD/MM/YYYY): 





7. Did you use any nursing home care due to your PD or PD related 
problems in the past 12 months? 
 
1. Yes, if yes, please specify total numbers of visits, nursing home care periods from 
(DD/MM/YYYY) to (DD/MM/YYYY) each time followed by nursing home care cost 
per time (S$): _____________________________________________________ 
____________________________________________________________________ 
2. No                                                          
□ 
 
 
 
 
 
